Melanoma: Pathogenesis and Targeted Therapy

Abstract

Melanoma is the most aggressive skin malignant tumor, typically exhibiting a high mutation burden and potentially harboring mutations in NRAS, BRAF, or NF1. To enhance survival rates, these driver alterations can achieve significant antitumor activity through targeted therapy. In the past decade, BRAF inhibitors combined with MEK inhibitors significantly improved the prognosis of BRAF mutation melanoma. Nevertheless, researchers have attempted various strategies to block the NRAS signaling pathway, NRAS mutation in melanoma is still considered to be untargetable. In recent years, MEK inhibitors like binimetinib and tunlametinib have displayed the efficacy for NRAS^mut melanoma, with tunlametinib being the first and only approved MEK inhibitor for advanced NRAS^mut melanoma. On the other hand, immune checkpoint inhibitors including PD-1/PD-L1 inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors changed the treatment landscape of advanced melanoma. In this review, we have summarized the current knowledge of molecular pathogenesis and classification of melanoma. Subsequently, we explored current and potential treatment approaches for melanoma, primarily encompassing BRAF inhibitors, MEK inhibitors, and immunotherapy, with a particular focus on their clinical relevance of development. Finally, the challenges in the treatment of melanoma, particularly in immunotherapy and targeted therapy, are summarized and discussed.

Keywords

BRAF / immunotherapy / melanoma / NRAS / targeted therapy

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 68 (2018): 394–424.

[2] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209–249.

[3] D. Schadendorf, A. C. J. van Akkooi, C. Berking, et al., “Melanoma,” Lancet (London, England) 392 (2018): 971–984.

[4] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2021,” CA: A Cancer Journal for Clinicians 71 (2021): 7–33.

[5] W. Guo, H. Wang, and C. Li, “Signal Pathways of Melanoma and Targeted Therapy,” Signal Transduction and Targeted Therapy 6 (2021): 424.

[6] L. Liu, W. Zhang, T. Gao, and C. Li, “Is UV an Etiological Factor of Acral Melanoma?,” Journal of Exposure Science & Environmental Epidemiology 26 (2016): 539–545.

[7] J. W. Chang, “Acral Melanoma: A Unique Disease in Asia,” JAMA Dermatology 149 (2013): 1272–1273.

[8] J. Wang, H. Jiang, F. Huang, et al., “Clinical Features and Response to Systemic Therapy in NRAS-mutant Chinese Melanoma Patients,” Journal of Cancer Research and Clinical Oncology 149 (2023): 701–708.

[9] A. Green, M. McCredie, R. MacKie, et al., “A Case-control Study of Melanomas of the Soles and Palms (Australia and Scotland),” Cancer Causes & Control: CCC 10 (1999): 21–25.

[10] C. M. Costello, M. R. Pittelkow, and A. R. Mangold, “Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot,” The New England Journal of Medicine 377 (2017): 395–396.

[11] A. E. Chang, L. H. Karnell, and H. R. Menck, “The National Cancer Data Base Report on Cutaneous and Noncutaneous Melanoma: A Summary of 84,836 Cases From the Past Decade. The American College of Surgeons Commission on Cancer and the American Cancer Society,” Cancer 83 (1998): 1664–1678.

[12] C. C. McLaughlin, X. Wu, A. Jemal, H. J. Martin, L. M. Roche, and V. W. Chen, “Incidence of Noncutaneous Melanomas in the U.S,” Cancer 103 (2005): 1000–1007.

[13] H. Y. Lee, W. Y. Chay, M. B. Tang, M. T. Chio, and S. H. Tan, “Melanoma: Differences Between Asian and Caucasian Patients,” Annals of the Academy of Medicine, Singapore 41 (2012): 17–20.

[14] S. Bellew, J. Q. Del Rosso, and G. K. Kim, “Skin Cancer in asians: Part 2: Melanoma,” The Journal of Clinical and Aesthetic Dermatology 2 (2009): 34–36.

[15] Y. L. Teh, W. L. Goh, S. H. Tan, et al., “Treatment and Outcomes of Melanoma in Asia: Results From the National Cancer Centre Singapore,” Asia-Pacific Journal of Clinical Oncology 14 (2018): e95–e102.

[16] D. N. Hu, G. P. Yu, S. A. McCormick, S. Schneider, and P. T. Finger, “Population-based Incidence of Uveal Melanoma in Various Races and Ethnic Groups,” American Journal of Ophthalmology 140 (2005): 612–617.

[17] G. Bollag, P. Hirth, J. Tsai, et al., “Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-mutant Melanoma,” Nature 467 (2010): 596–599.

[18] J. A. Sosman, K. B. Kim, L. Schuchter, et al., “Survival in BRAF V600-mutant Advanced Melanoma Treated With vemurafenib,” The New England Journal of Medicine 366 (2012): 707–714.

[19] G. V. Long, D. Stroyakovskiy, H. Gogas, et al., “Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma,” The New England Journal of Medicine 371 (2014): 1877–1888.

[20] C. Robert, J. J. Grob, D. Stroyakovskiy, et al., “Five-Year Outcomes With Dabrafenib plus Trametinib in Metastatic Melanoma,” The New England Journal of Medicine 381 (2019): 626–636.

[21] R. Gutzmer, D. Stroyakovskiy, H. Gogas, et al., “Atezolizumab, vemurafenib, and Cobimetinib as First-line Treatment for Unresectable Advanced BRAF(V600) Mutation-positive Melanoma (IMspire150): Primary Analysis of the Randomised, Double-blind, Placebo-controlled, Phase 3 Trial,” Lancet (London, England) 395 (2020): 1835–1844.

[22] P. A. Ascierto, D. Stroyakovskiy, H. Gogas, et al., “Overall Survival With First-line Atezolizumab in Combination With Vemurafenib and Cobimetinib in BRAF(V600) Mutation-positive Advanced Melanoma (IMspire150): Second Interim Analysis of a Multicentre, Randomised, Phase 3 Study,” The Lancet Oncology 24 (2023): 33–44.

[23] R. Dummer, P. Queirolo, A. M. Abajo Guijarro, et al., “Atezolizumab, vemurafenib, and cobimetinib in Patients With Melanoma With CNS Metastases (TRICOTEL): A Multicentre, Open-label, Single-arm, Phase 2 Study,” The Lancet Oncology 23 (2022): 1145–1155.

[24] P. A. Ascierto, P. F. Ferrucci, R. Fisher, et al., “Dabrafenib, Trametinib and Pembrolizumab or Placebo in BRAF-mutant Melanoma,” Nature Medicine 25 (2019): 941–946.

[25] D. E. Elder, B. C. Bastian, I. A. Cree, D. Massi, and R. A. Scolyer, “The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway,” Archives of Pathology & Laboratory Medicine 144 (2020): 500–522.

[26] J. A. Curtin, J. Fridlyand, T. Kageshita, et al., “Distinct Sets of Genetic Alterations in Melanoma,” The New England Journal of Medicine 353 (2005): 2135–2147.

[27] J. A. Carlson, A. Slominski, G. P. Linette, M. C. Mihm, and J. S. Ross, “Biomarkers in Melanoma: Predisposition, Screening and Diagnosis,” Expert Review of Molecular Diagnostics 3, no. 2 (2003): 163–184.

[28] J. Tímár and A. Ladányi, “Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction,” International Journal of Molecular Sciences 23 (2022), https://doi.org/10.3390/ijms23105384.

[29] C. Teixido, P. Castillo, C. Martinez-Vila, A. Arance, and L. Alos, “Molecular Markers and Targets in Melanoma,” Cells 10, no. 9 (2021): 2320.

[30] N. G. Ordóñez, “Value of Melanocytic-associated Immunohistochemical Markers in the Diagnosis of Malignant Melanoma: A Review and Update,” Human Pathology 45 (2014): 191–205.

[31] D. C. Deacon, E. A. Smith, and R. L. Judson-Torres, “Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects,” Frontiers in Medicine (Lausanne) 8, 642380, (2021).

[32] A. Uguen, M. Talagas, S. Costa, et al., “A p16-Ki-67-HMB45 Immunohistochemistry Scoring System as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma,” Diagnostic Pathology 10 (2015): 195.

[33] H. Davies, G. R. Bignell, C. Cox, et al., “Mutations of the BRAF Gene in human Cancer,” Nature 417 (2002): 949–954.

[34] C. M. Lovly, K. B. Dahlman, L. E. Fohn, et al., “Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-driven Therapeutic Trials,” PLoS ONE 7 (2012): e35309.

[35] M. V. Heppt, T. Siepmann, J. Engel, et al., “Prognostic Significance of BRAF and NRAS Mutations in Melanoma: A German Study From Routine Care,” BMC Cancer 17 (2017): 536.

[36] G. A. Hobbs, C. J. Der, and K. L. Rossman, “RAS Isoforms and Mutations in Cancer at a Glance,” Journal of Cell Science 129 (2016): 1287–1292.

[37] I. A. Prior, P. D. Lewis, and C. Mattos, “A Comprehensive Survey of Ras Mutations in Cancer,” Cancer Research 72 (2012): 2457–2467.

[38] S. J. Heidorn, C. Milagre, S. Whittaker, et al., “Kinase-dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression Through CRAF,” Cell 140 (2010): 209–221.

[39] P. M. Lokhandwala, L. Tseng, E. Rodriguez, et al., “Clinical Mutational Profiling and Categorization of BRAF Mutations in Melanomas Using next Generation Sequencing,” BMC Cancer 19 (2019): 665.

[40] L. Si, Y. Kong, X. Xu, et al., “Prevalence of BRAF V600E Mutation in Chinese Melanoma Patients: Large Scale Analysis of BRAF and NRAS Mutations in a 432-case Cohort,” European Journal of Cancer (Oxford, England: 1990) 48 (2012): 94–100.

[41] X. Bai, Y. Kong, Z. Chi, et al., “MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23 (2017): 6120–6127.

[42] J. A. Jakob, R. L. Bassett, C. S. Ng, et al., “NRAS Mutation Status Is an Independent Prognostic Factor in Metastatic Melanoma,” Cancer 118 (2012): 4014–4023.

[43] B. Devitt, W. Liu, R. Salemi, et al., “Clinical Outcome and Pathological Features Associated With NRAS Mutation in Cutaneous Melanoma,” Pigment Cell & Melanoma Research 24 (2011): 666–672.

[44] N. K. Hayward, J. S. Wilmott, N. Waddell, et al., “Whole-genome Landscapes of Major Melanoma Subtypes,” Nature 545 (2017): 175–180.

[45] E. Dika, G. Veronesi, A. Altimari, et al., “BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients,” American Journal of Clinical Pathology 153 (2020): 664–671.

[46] A. Zebary, K. Omholt, I. Vassilaki, et al., “KIT, NRAS, BRAF and PTEN Mutations in a Sample of Swedish Patients With Acral Lentiginous Melanoma,” Journal of Dermatological Science 72 (2013): 284–289.

[47] J. H. Shim, H. Shin, J. Park, et al., “Mutational Profiling of Acral Melanomas in Korean Populations,” Experimental Dermatology 26 (2017): 883–888.

[48] R. Huang, G. Shen, Y. Ren, et al., “Prognostic Value of Genetic Aberrations and Tumor Immune Microenvironment in Primary Acral Melanoma,” Journal of Translational Medicine 21 (2023): 78.

[49] J. Yan, X. Wu, J. Yu, et al., “Analysis of NRAS Gain in 657 Patients With Melanoma and Evaluation of Its Sensitivity to a MEK Inhibitor,” European Journal of Cancer (Oxford, England: 1990) 89 (2018): 90–101.

[50] N. Dumaz, F. Jouenne, J. Delyon, S. Mourah, A. Bensussan, and C. Lebbé, “Atypical BRAF and NRAS Mutations in Mucosal Melanoma,” Cancers 11, no. 8 (2019): 1133.

[51] K. W. Nassar and A. C. Tan, “The Mutational Landscape of Mucosal Melanoma,” Seminars in Cancer Biology 61 (2020): 139–148.

[52] J. P. Wróblewska, D. Dias-Santagata, A. Ustaszewski, et al., “Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas,” Cells 10, no. 9 (2021): 2216.

[53] F. Cruz 3rd, B. P. Rubin, D. Wilson, et al., “Absence of BRAF and NRAS Mutations in Uveal Melanoma,” Cancer Research 63, no. 18 (2003): 5761–5766.

[54] J. F. Hancock, “Ras Proteins: Different Signals From Different Locations,” Nature Reviews Molecular Cell Biology 4 (2003): 373–384.

[55] I. M. Ahearn, K. Haigis, D. Bar-Sagi, and M. R. Philips, “Regulating the Regulator: Post-translational Modification of RAS,” Nature Reviews Molecular Cell Biology 13 (2011): 39–51.

[56] S. Li, A. Balmain, and C. M. Counter, “A Model for RAS Mutation Patterns in Cancers: Finding the Sweet Spot,” Nature Reviews Cancer 18 (2018): 767–777.

[57] J. L. Bos, H. Rehmann, and A. Wittinghofer, “GEFs and GAPs: Critical Elements in the Control of Small G Proteins,” Cell 129 (2007): 865–877.

[58] D. K. Simanshu, D. V. Nissley, and F. McCormick, “RAS Proteins and Their Regulators in Human Disease,” Cell 170 (2017): 17–33.

[59] A. D. Cox, S. W. Fesik, A. C. Kimmelman, J. Luo, and C. J. Der, “Drugging the Undruggable RAS: Mission Possible?,” Nature Reviews Drug Discovery 13 (2014): 828–851.

[60] Y. Pylayeva-Gupta, E. Grabocka, and D. Bar-Sagi, “RAS Oncogenes: Weaving a Tumorigenic Web,” Nature Reviews Cancer 11 (2011): 761–774.

[61] J. M. Ostrem and K. M. Shokat, “Direct Small-molecule Inhibitors of KRAS: From Structural Insights to Mechanism-based Design,” Nature Reviews Drug Discovery 15 (2016): 771–785.

[62] I. V. Fedorenko, G. T. Gibney, and K. S. Smalley, “NRAS Mutant Melanoma: Biological Behavior and Future Strategies for Therapeutic Management,” Oncogene 32 (2013): 3009–3018.

[63] N. Dumaz, R. Hayward, J. Martin, et al., “In Melanoma, RAS Mutations Are Accompanied by Switching Signaling From BRAF to CRAF and Disrupted Cyclic AMP Signaling,” Cancer Research 66 (2006): 9483–9491.

[64] A. Marquette, J. André, M. Bagot, A. Bensussan, and N. Dumaz, “ERK and PDE4 Cooperate to Induce RAF Isoform Switching in Melanoma,” Nature Structural & Molecular Biology 18 (2011): 584–591.

[65] C. Posch, H. Moslehi, L. Feeney, et al., “Combined Targeting of MEK and PI3K/mTOR Effector Pathways Is Necessary to Effectively Inhibit NRAS Mutant Melanoma in Vitro and in Vivo,” Proceedings of the National Academy of Sciences of the United States of America 110 (2013): 4015–4020.

[66] M. Gao, H. Wang, X. Chen, et al., “Aberrant Modulation of Ribosomal Protein S6 Phosphorylation Confers Acquired Resistance to MAPK Pathway Inhibitors in BRAF-mutant Melanoma,” Acta Pharmacologica Sinica 40 (2019): 268–278.

[67] S. M. Wilhelm, C. Carter, L. Tang, et al., “BAY 43–9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis,” Cancer Research 64 (2004): 7099–7109.

[68] K. E. Sheppard and G. A. McArthur, “The Cell-cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma,” Clinical Cancer Research: An Official Journal of the 19 (2013): 5320–5328.

[69] Y. Li, M. A. Nichols, J. W. Shay, and Y. Xiong, “Transcriptional Repression of the D-type Cyclin-dependent Kinase Inhibitor p16 by the Retinoblastoma Susceptibility Gene Product pRb,” Cancer Research 54 (1994): 6078–6082.

[70] T. Randic, I. Kozar, C. Margue, J. Utikal, and S. Kreis, “NRAS Mutant Melanoma: Towards Better Therapies,” Cancer Treatment Reviews 99 (2021): 102238.

[71] C. Yan and D. Theodorescu, “RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer,” Pharmacological Reviews 70 (2018): 1–11.

[72] D. S. Richardson, J. M. Spehar, D. T. Han, P. A. Chakravarthy, and S. T. Sizemore, “The RAL Enigma: Distinct Roles of RALA and RALB in Cancer,” Cells 11, no. 10 (2022): 1645.

[73] P. A. Zipfel, D. C. Brady, D. F. Kashatus, B. D. Ancrile, D. S. Tyler, and C. M. Counter, “Ral Activation Promotes Melanomagenesis,” Oncogene 29 (2010): 4859–4864.

[74] P. J. Mishra, L. Ha, J. Rieker, et al., “Dissection of RAS Downstream Pathways in Melanomagenesis: A Role for Ral in Transformation,” Oncogene 29 (2010): 2449–2456.

[75] S. C. Falsetti, D. Wang, H. Peng, et al., “Geranylgeranyltransferase I Inhibitors Target RalB to Inhibit Anchorage-dependent Growth and Induce Apoptosis and RalA to Inhibit Anchorage-independent Growth,” Molecular and Cellular Biology 27 (2007): 8003–8014.

[76] E. Edlundh-Rose, S. Egyházi, K. Omholt, et al., “NRAS and BRAF Mutations in Melanoma Tumours in Relation to Clinical Characteristics: A Study Based on Mutation Screening by Pyrosequencing,” Melanoma Research 16, no. 6 (2006): 471–478.

[77] K. Sakaizawa, A. Ashida, A. Uchiyama, et al., “Clinical Characteristics Associated With BRAF, NRAS and KIT Mutations in Japanese Melanoma Patients,” Journal of Dermatological Science 80 (2015): 33–37.

[78] A. Viros, J. Fridlyand, J. Bauer, et al., “Improving Melanoma Classification by Integrating Genetic and Morphologic Features,” PLoS Medicine 5 (2008): e120.

[79] J. A. Ellerhorst, V. R. Greene, S. Ekmekcioglu, et al., “Clinical Correlates of NRAS and BRAF Mutations in Primary human Melanoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 17 (2011): 229–235.

[80] P. W. Sperduto, W. Jiang, P. D. Brown, et al., “The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients with Brain Metastases,” International Journal of Radiation Oncology, Biology, Physics 98 (2017): 1069–1077.

[81] M. Colombino, M. Capone, A. Lissia, et al., “BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 (2012): 2522–2529.

[82] P. Fang, N. S. Boehling, E. J. Koay, et al., “Melanoma Brain Metastases Harboring BRAF (V600K) or NRAS Mutations Are Associated With an Increased Local Failure Rate Following Conventional Therapy,” Journal of Neuro-Oncology 137 (2018): 67–75.

[83] G. K. In, K. Poorman, M. Saul, et al., “Molecular Profiling of Melanoma Brain Metastases Compared to Primary Cutaneous Melanoma and to Extracranial Metastases,” Oncotarget 11 (2020): 3118–3128.

[84] J. M. Cloutier, M. Wang, S. S. Vemula, et al., “Amplification of Mutant NRAS in Melanocytic Tumors With Features of Spitz Tumors,” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 37, no. 5 (2024): 100469.

[85] Y. Yarden, W. J. Kuang, T. Yang-Feng, et al., “Human Proto-oncogene c-kit: A New Cell Surface Receptor Tyrosine Kinase for an Unidentified Ligand,” Embo Journal 6 (1987): 3341–3351.

[86] C. Cohen, A. Zavala-Pompa, J. H. Sequeira, et al., “Mitogen-actived Protein Kinase Activation Is an Early Event in Melanoma Progression,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 8, no. 12 (2002): 3728–3733.

[87] D. Handolias, R. Salemi, W. Murray, et al., “Mutations in KIT Occur at Low Frequency in Melanomas Arising From Anatomical Sites Associated With Chronic and Intermittent Sun Exposure,” Pigment Cell & Melanoma Research 23 (2010): 210–215.

[88] J. Guo, L. Si, Y. Kong, et al., “Phase II, Open-label, Single-arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29 (2011): 2904–2909.

[89] R. D. Carvajal, C. R. Antonescu, J. D. Wolchok, et al., “KIT as a Therapeutic Target in Metastatic Melanoma,” Jama 305, no. 22 (2011): 2327–2334.

[90] J. Guo, R. Carvajal, R. Dummer, et al., “Efficacy and Safety of nilotinib in Patients With KIT-mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-arm, Phase II TEAM Trial,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 28 (2017): 1380–1387.

[91] A. Hauschild, J. Grob, L. V. Demidov, et al., “Dabrafenib in BRAF-mutated Metastatic Melanoma: A Multicentre, Open-label, Phase 3 Randomised Controlled Trial,” Lancet (London, England) 380 (2012): 358–365.

[92] P. B. Chapman, A. Hauschild, C. Robert, et al., “Improved Survival With vemurafenib in Melanoma With BRAF V600E Mutation,” The New England Journal of Medicine 364 (2011): 2507–2516.

[93] K. T. Flaherty, I. Puzanov, K. B. Kim, et al., “Inhibition of Mutated, Activated BRAF in Metastatic Melanoma,” The New England Journal of Medicine 363 (2010): 809–819.

[94] D. B. Solit and N. Rosen, “Resistance to BRAF Inhibition in Melanomas,” The New England Journal of Medicine 364 (2011): 772–774.

[95] R. Nazarian, H. Shi, Q. Wang, et al., “Melanomas Acquire Resistance to B-RAF(V600E) Inhibition by RTK or N-RAS Upregulation,” Nature 468 (2010): 973–977.

[96] P. A. Oberholzer, D. Kee, P. Dziunycz, et al., “RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 (2012): 316–321.

[97] L. Boussemart, E. Routier, C. Mateus, et al., “Prospective Study of Cutaneous Side-effects Associated With the BRAF Inhibitor vemurafenib: A Study of 42 Patients,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 24 (2013): 1691–1697.

[98] F. Su, A. Viros, C. Milagre, et al., “RAS Mutations in Cutaneous Squamous-cell Carcinomas in Patients Treated With BRAF Inhibitors,” The New England Journal of Medicine 366 (2012): 207–215.

[99] K. T. Flaherty, J. R. Infante, A. Daud, et al., “Combined BRAF and MEK Inhibition in Melanoma With BRAF V600 Mutations,” The New England Journal of Medicine 367 (2012): 1694–1703.

[100] J. Larkin, P. A. Ascierto, B. Dréno, et al., “Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma,” The New England Journal of Medicine 371 (2014): 1867–1876.

[101] C. Robert, B. Karaszewska, J. Schachter, et al., “Improved Overall Survival in Melanoma With Combined Dabrafenib and Trametinib,” The New England Journal of Medicine 372, no. 1 (2015): 30–39.

[102] G. Long, K. Flaherty, D. Stroyakovskiy, et al., “Dabrafenib plus trametinib versus Dabrafenib Monotherapy in Patients With Metastatic BRAF V600E/K-mutant Melanoma: Long-term Survival and Safety Analysis of a Phase 3 Study,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 28 (2017): 1631–1639.

[103] P. A. Ascierto, G. A. McArthur, B. Dréno, et al., “Cobimetinib Combined With vemurafenib in Advanced BRAF(V600)-mutant Melanoma (coBRIM): Updated Efficacy Results From a Randomised, Double-blind, Phase 3 Trial,” The Lancet Oncology 17 (2016): 1248–1260.

[104] J. Delord, C. Robert, M. Nyakas, et al., “Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 23 (2017): 5339–5348.

[105] R. Dummer, P. A. Ascierto, H. J. Gogas, et al., “Encorafenib plus binimetinib versus vemurafenib or encorafenib in Patients With BRAF-mutant Melanoma (COLUMBUS): A Multicentre, Open-label, Randomised Phase 3 Trial,” The Lancet Oncology 19 (2018): 603–615.

[106] R. Dummer, P. A. Ascierto, H. J. Gogas, et al., “Overall Survival in Patients With BRAF-mutant Melanoma Receiving Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib (COLUMBUS): A Multicentre, Open-label, Randomised, Phase 3 Trial,” The Lancet Oncology 19 (2018): 1315–1327.

[107] A. D. Cox and C. J. Der, “Ras History: The Saga Continues,” Small GTPases 1 (2010): 2–27.

[108] N. Berndt, A. D. Hamilton, and S. M. Sebti, “Targeting Protein Prenylation for Cancer Therapy,” Nature Reviews Cancer 11 (2011): 775–791.

[109] K. Zhu, A. D. Hamilton, and S. M. Sebti, “Farnesyltransferase Inhibitors as Anticancer Agents: Current Status,” Current Opinion in Investigational Drugs (London, England: 2000) 4 (2003): 1428–1435.

[110] D. W. End, G. Smets, A. V. Todd, et al., “Characterization of the Antitumor Effects of the Selective Farnesyl Protein Transferase Inhibitor R115777 in Vivo and in Vitro,” Cancer Research 61 (2001): 131–137.

[111] F. R. Khuri, B. S. Glisson, E. S. Kim, et al., “Phase I Study of the Farnesyltransferase Inhibitor lonafarnib With paclitaxel in Solid Tumors,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 10 (2004): 2968–2976.

[112] H. Niessner, D. Beck, T. Sinnberg, et al., “The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-induced Apoptosis in Melanoma Cells,” The Journal of Investigative Dermatology 131 (2011): 468–479.

[113] C. J. Punt, L. van Maanen, C. J. Bol, W. F. Seifert, and D. J. Wagener, “Phase I and Pharmacokinetic Study of the Orally Administered Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Solid Tumors,” Anti-Cancer Drugs 12 (2001): 193–197.

[114] M. Crul, G. J. de Klerk, M. Swart, et al., “Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 20 (2002): 2726–2735.

[115] T. F. Gajewski, A. K. Salama, D. Niedzwiecki, et al., “Phase II Study of the Farnesyltransferase Inhibitor R115777 in Advanced Melanoma (CALGB 500104),” Journal of Translational Medicine 10 (2012): 246.

[116] R. E. Marks, A. W. Ho, C. Robbel, T. Kuna, S. Berk, and T. F. Gajewski, “Farnesyltransferase Inhibitors Inhibit T-cell Cytokine Production at the Posttranscriptional Level,” Blood 110 (2007): 1982–1988.

[117] K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, and S. D. Merajver, “Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment With a Farnesyl Transferase Inhibitor,” Molecular Cancer Therapeutics 1, no. 8 (2002): 575–583.

[118] J. Han, S. H. Oh, F. Morgillo, et al., “Hypoxia-inducible Factor 1alpha and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in human Aerodigestive Tract Cancer,” Journal of the National Cancer Institute 97 (2005): 1272–1286.

[119] A. D. Basso, A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier, “The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling. Role in FTI Enhancement of Taxane and Tamoxifen Anti-tumor Activity,” The Journal of Biological Chemistry 280 (2005): 31101–31108.

[120] D. S. Hong, S. M. Sebti, R. A. Newman, et al., “Phase I Trial of a Combination of the Multikinase Inhibitor sorafenib and the Farnesyltransferase Inhibitor tipifarnib in Advanced Malignancies,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15 (2009): 7061–7068.

[121] D. B. Whyte, P. Kirschmeier, T. N. Hockenberry, et al., “K- and N-Ras Are Geranylgeranylated in Cells Treated With Farnesyl Protein Transferase Inhibitors,” The Journal of Biological Chemistry 272 (1997): 14459–14464.

[122] A. L. Ho, I. Brana, R. Haddad, et al., “Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39 (2021): 1856–1864.

[123] K. Tateishi, M. Tsubaki, T. Takeda, et al., “FTI-277 and GGTI-289 Induce Apoptosis via Inhibition of the Ras/ERK and Ras/mTOR Pathway in Head and Neck Carcinoma HEp-2 and HSC-3 Cells,” Journal of BUON: Official Journal of the Balkan Union of Oncology 26, no. 2 (2021): 606–612.

[124] E. C. Lerner, T. Zhang, D. B. Knowles, Y. Qian, A. D. Hamilton, and S. M. Sebti, “Inhibition of the Prenylation of K-Ras, but Not H- or N-Ras, Is Highly Resistant to CAAX Peptidomimetics and Requires both a Farnesyltransferase and a Geranylgeranyltransferase I Inhibitor in human Tumor Cell Lines,” Oncogene 15 (1997): 1283–1288.

[125] J. Sun, Y. Qian, A. D. Hamilton, and S. M. Sebti, “Both Farnesyltransferase and Geranylgeranyltransferase I Inhibitors Are Required for Inhibition of Oncogenic K-Ras Prenylation but Each Alone Is Sufficient to Suppress human Tumor Growth in Nude Mouse Xenografts,” Oncogene 16 (1998): 1467–1473.

[126] K. A. Margolin, J. Moon, L. E. Flaherty, et al., “Randomized Phase II Trial of sorafenib With temsirolimus or tipifarnib in Untreated Metastatic Melanoma (S0438),” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18 (2012): 1129–1137.

[127] K. Jazieh, J. Molina, J. Allred, et al., “A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination With the Epidermal Growth Factor Tyrosine Kinase Inhibitor Erlotinib in Patients With Advanced Solid Tumors,” Investigational New Drugs 37 (2019): 307–314.

[128] A. M. Sjogren, K. M. Andersson, M. Liu, et al., “GGTase-I Deficiency Reduces Tumor Formation and Improves Survival in Mice With K-RAS-induced Lung Cancer,” The Journal of Clinical Investigation 117 (2007): 1294–1304.

[129] M. Liu, A. M. Sjogren, C. Karlsson, et al., “Targeting the Protein Prenyltransferases Efficiently Reduces Tumor Development in Mice With K-RAS-induced Lung Cancer,” Proceedings of the National Academy of Sciences of the United States of America 107 (2010): 6471–6476.

[130] M. A. Morgan, T. Sebil, E. Aydilek, D. Peest, A. Ganser, and C. W. M. Reuter, “Combining Prenylation Inhibitors Causes Synergistic Cytotoxicity, Apoptosis and Disruption of RAS-to-MAP Kinase Signalling in Multiple Myeloma Cells,” British Journal of Haematology 130 (2005): 912–925.

[131] R. B. Lobell, C. A. Omer, M. T. Abrams, et al., “Evaluation of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Inhibitor Combinations in Preclinical Models,” Cancer Research 61, no. 24 (2001): 8758–8768.

[132] A. Kazi, S. Xiang, H. Yang, et al., “Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25 (2019): 5984–5996.

[133] U. N. Wasko, J. Jiang, A. Curiel-Garcia, et al., “Tumor-selective Effects of Active RAS Inhibition in Pancreatic Ductal Adenocarcinoma,” Biorxiv: The Preprint Server for Biology (2023), https://doi.org/10.1101/2023.12.03.569791.

[134] U. N. Wasko, J. Jiang, T. C. Dalton, et al., “Tumor-selective Activity of RAS-GTP Inhibition in Pancreatic Cancer,” Nature 629, no. 8013 (2024): 927–936.

[135] M. Holderfield, B. J. Lee, J. Jiang, et al., “Concurrent Inhibition of Oncogenic and Wild-type RAS-GTP for Cancer Therapy,” Nature 629, no. 8013 (2024): 919–926.

[136] J. Jiang, L. Jiang, B. J. Maldonato, et al., “Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers,” Cancer Discovery 14, no. 6 (2024): 994–1017.

[137] C. J. Schulze, K. J. Seamon, Y. Zhao, et al., “Chemical Remodeling of a Cellular Chaperone to Target the Active state of Mutant KRAS,” Science (New York, NY) 381 (2023): 794–799.

[138] F. Skoulidis, B. T. Li, G. K. Dy, et al., “Sotorasib for Lung Cancers With KRAS p.G12C Mutation,” The New England Journal of Medicine 384 (2021): 2371–2381.

[139] A. J. de Langen, M. L. Johnson, J. Mazieres, et al., “Sotorasib versus docetaxel for Previously Treated Non-small-cell Lung Cancer With KRAS(G12C) Mutation: A Randomised, Open-label, Phase 3 Trial,” Lancet (London, England) 401 (2023): 733–746.

[140] J. Canon, K. Rex, A. Y. Saiki, et al., “The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-tumour Immunity,” Nature 575 (2019): 217–223.

[141] S. S. Zhang and M. Nagasaka, “Spotlight on Sotorasib (AMG 510) for KRAS (G12C) Positive Non-Small Cell Lung Cancer,” Lung Cancer (Auckland, NZ) 12 (2021): 115–122.

[142] D. S. Hong, M. G. Fakih, J. H. Strickler, et al., “KRAS(G12C) Inhibition With Sotorasib in Advanced Solid Tumors,” The New England Journal of Medicine 383 (2020): 1207–1217.

[143] D. A. Rubinson, N. Tanaka, F. Fece de la Cruz, et al., “Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers,” Cancer Discovery 14, no. 5 (2024): 727–736.

[144] U. Degirmenci, M. Wang, and J. Hu, “Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy,” Cells 9, no. 1 (2020): 198.

[145] L. Möhrmann, A. Cuberi, S. Brückmann, et al., “Response to (K)RAS(G12C) and EGFR Inhibition in a Patient with NRAS(G12C)-Mutated Rectal Cancer,” JCO Precision Oncology 7 (2023): e2200666.

[146] X. Chen, S. Liu, D. Han, D. Han, W. Sun, and X. Zhao, “Regulation of Melanoma Malignancy by the RP11-705C15.3/miR-145-5p/NRAS/MAPK Signaling Axis,” Cancer Gene Therapy 28 (2021): 1198–1212.

[147] S. Liu, G. Gao, D. Yan, et al., “Effects of miR-145-5p Through NRAS on the Cell Proliferation, Apoptosis, Migration, and Invasion in Melanoma by Inhibiting MAPK and PI3K/AKT Pathways,” Cancer Medicine 6 (2017): 819–833.

[148] X. Chen, S. Liu, D. Han, et al., “FUT8-AS1 Inhibits the Malignancy of Melanoma through Promoting miR-145-5p Biogenesis and Suppressing NRAS/MAPK Signaling,” Frontiers in Oncology 10 (2020): 586085.

[149] J. M. Pang, P. Chien, M. Kao, et al., “MicroRNA-708 Emerges as a Potential Candidate to Target Undruggable NRAS,” PLoS ONE 18 (2023): e0284744.

[150] M. Eskandarpour, S. Kiaii, C. Zhu, J. Castro, A. J. Sakko, and J. Hansson, “Suppression of Oncogenic NRAS by RNA Interference Induces Apoptosis of human Melanoma Cells,” International Journal of Cancer 115 (2005): 65–73.

[151] X. Chen, G. Tang, J. Dai, et al., “Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma,” Journal of Medicinal Chemistry 66 (2023): 5171–5184.

[152] K. Kawauchi, W. Sugimoto, T. Yasui, et al., “An Anionic Phthalocyanine Decreases NRAS Expression by Breaking Down Its RNA G-quadruplex,” Nature Communications 9 (2018): 2271.

[153] M. Maio, K. Lewis, L. Demidov, et al., “Adjuvant Vemurafenib in Resected, BRAF(V600) Mutation-positive Melanoma (BRIM8): A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Trial,” The Lancet Oncology 19 (2018): 510–520.

[154] G. Hatzivassiliou, K. Song, I. Yen, et al., “RAF Inhibitors Prime Wild-type RAF to Activate the MAPK Pathway and Enhance Growth,” Nature 464 (2010): 431–435.

[155] M. Holderfield, H. Merritt, J. Chan, et al., “RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation,” Cancer Cell 23 (2013): 594–602.

[156] G. S. Falchook, K. D. Lewis, J. R. Infante, et al., “Activity of the Oral MEK Inhibitor trametinib in Patients With Advanced Melanoma: A Phase 1 Dose-escalation Trial,” The Lancet Oncology 13 (2012): 782–789.

[157] P. A. Ascierto, D. Schadendorf, C. Berking, et al., “MEK162 for Patients With Advanced Melanoma Harbouring NRAS or Val600 BRAF Mutations: A Non-randomised, Open-label Phase 2 Study,” The Lancet Oncology 14 (2013): 249–256.

[158] R. Dummer, D. Schadendorf, P. A. Ascierto, et al., “Binimetinib versus Dacarbazine in Patients With Advanced NRAS-mutant Melanoma (NEMO): A Multicentre, Open-label, Randomised, Phase 3 Trial,” The Lancet Oncology 18 (2017): 435–445.

[159] J. M. Cleary, V. Wang, R. S. Heist, et al., “Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients With NRAS-Mutated Tumors,” Clinical Cancer Research: An Official Journal of the 27 (2021): 2996–3004.

[160] L. Mao, J. Guo, L. Zhu, et al., “A First-in-human, Phase 1a Dose-escalation Study of the Selective MEK1/2 Inhibitor FCN-159 in Patients With Advanced NRAS-mutant Melanoma,” European Journal of Cancer (Oxford, England: 1990) 175 (2022): 125–135.

[161] X. Wang, Z. Luo, J. Chen, et al., “First-in-human Phase I Dose-escalation and Dose-expansion Trial of the Selective MEK Inhibitor HL-085 in Patients With Advanced Melanoma Harboring NRAS Mutations,” BMC Medicine 21 (2023): 2.

[162] Q. Zhao, T. Wang, H. Wang, et al., “Phase I Pharmacokinetic Study of an Oral, Small-molecule MEK Inhibitor Tunlametinib in Patients With Advanced NRAS Mutant Melanoma,” Frontiers in Pharmacology 13 (2022): 1039416.

[163] C. Lebbé, A. Italiano, N. Houédé, et al., “Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial,” Targeted Oncology 16 (2021): 47–57.

[164] C. Lebbé, C. Dutriaux, T. Lesimple, et al., “Pimasertib versus Dacarbazine in Patients with Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial With Crossover,” Cancers 12, no. 7 (2020): 1727.

[165] R. D. Carvajal, J. A. Sosman, J. F. Quevedo, et al., “Effect of selumetinib vs Chemotherapy on Progression-free Survival in Uveal Melanoma: A Randomized Clinical Trial,” Jama 311 (2014): 2397–2405.

[166] J. M. Kirkwood, L. Bastholt, C. Robert, et al., “Phase II, Open-label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients With Advanced Melanoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18 (2012): 555–567.

[167] L. Zimmer, F. Barlesi, M. Martinez-Garcia, et al., “Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients With Advanced Cancer With RAS-RAF Mutations,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20 (2014): 4251–4261.

[168] S. Leijen, M. R. Middleton, P. Tresca, et al., “Phase I Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients With Advanced Solid Tumors,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18 (2012): 4794–4805.

[169] X. Wei, Z. Zou, W. Zhang, et al., “A Phase II Study of Efficacy and Safety of the MEK Inhibitor tunlametinib in Patients With Advanced NRAS-mutant Melanoma,” European Journal of Cancer (Oxford, England: 1990) 202 (2024): 114008.

[170] V. W. Rebecca, G. M. Alicea, K. H. T. Paraiso, H. Lawrence, G. T. Gibney, and K. S. M. Smalley, “Vertical Inhibition of the MAPK Pathway Enhances Therapeutic Responses in NRAS-mutant Melanoma,” Pigment Cell & Melanoma Research 27 (2014): 1154–1158.

[171] A. V. Matter, S. Micaletto, U. Urner-Bloch, R. Dummer, and S. M. Goldinger, “Long-Term Response to Intermittent Binimetinib in Patients With NRAS-Mutant Melanoma,” The Oncologist 25 (2020): e1593–e1597.

[172] M. C. Zipser, O. M. Eichhoff, D. S. Widmer, et al., “A Proliferative Melanoma Cell Phenotype Is Responsive to RAF/MEK Inhibition Independent of BRAF Mutation Status,” Pigment Cell & Melanoma Research 24 (2011): 326–333.

[173] M. A. Deken, J. Gadiot, E. S. Jordanova, et al., “Targeting the MAPK and PI3K Pathways in Combination With PD1 Blockade in Melanoma,” Oncoimmunology 5 (2016): e1238557.

[174] T. Jin, H. Lavoie, M. Sahmi, et al., “RAF Inhibitors Promote RAS-RAF Interaction by Allosterically Disrupting RAF Autoinhibition,” Nature Communications 8 (2017): 1211.

[175] P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, and N. Rosen, “RAF Inhibitors Transactivate RAF Dimers and ERK Signalling in Cells With Wild-type BRAF,” Nature 464 (2010): 427–430.

[176] G. Awada, J. K. Schwarze, J. Tijtgat, G. Fasolino, H. Everaert, and B. Neyns, “A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients With Advanced Pretreated NRAS(Q61R/K/L) Mutant Melanoma (TraMel-WT),” Cancers 13, no. 9 (2021): 2010.

[177] P. Lito, A. Saborowski, J. Yue, et al., “Disruption of CRAF-mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors,” Cancer Cell 25 (2014): 697–710.

[178] C. Dorard, C. Estrada, C. Barbotin, et al., “RAF Proteins Exert both Specific and Compensatory Functions During Tumour Progression of NRAS-driven Melanoma,” Nature Communications 8 (2017): 15262.

[179] E. Tkacik, K. Li, G. Gonzalez-Del Pino, et al., “Structure and RAF family Kinase Isoform Selectivity of Type II RAF Inhibitors tovorafenib and naporafenib,” The Journal of Biological Chemistry 299 (2023): 104634.

[180] Y. K. Chen, T. Kanouni, L. D. Arnold, et al., “The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition,” Journal of Medicinal Chemistry 67 (2024): 1747–1757.

[181] A. Nakamura, T. Arita, S. Tsuchiya, et al., “Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-resistant Melanoma,” Cancer Research 73 (2013): 7043–7055.

[182] K. Monaco, S. Delach, J. Yuan, et al., “LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27 (2021): 2061–2073.

[183] F. de Braud, C. Dooms, R. S. Heist, et al., “Initial Evidence for the Efficacy of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma: Results from the Expansion Arm of a Phase Ib, Open-Label Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 2651–2660.

[184] F. Janku, T. M. Kim, G. Iyer, et al., “First-in-human Study of naporafenib (LXH254) With or Without spartalizumab in Adult Patients With Advanced Solid Tumors Harboring MAPK Signaling Pathway Alterations,” European Journal of Cancer (Oxford, England: 1990) 196 (2024): 113458.

[185] I. Yen, F. Shanahan, J. Lee, et al., “ARAF Mutations Confer Resistance to the RAF Inhibitor belvarafenib in Melanoma,” Nature 594 (2021): 418–423.

[186] K. H. Kim, S. Cho, Y. Jeong, et al., “Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients With RAS/RAF-Mutant Melanoma,” The Oncologist 29 (2024): e811–e821.

[187] D. W. Rasco, T. Medina, P. Corrie, et al., “Phase 1 Study of the Pan-RAF Inhibitor tovorafenib in Patients With Advanced Solid Tumors Followed by Dose Expansion in Patients With Metastatic Melanoma,” Cancer Chemotherapy and Pharmacology 92 (2023): 15–28.

[188] M. Atefi, B. Titz, E. Avramis, et al., “Combination of Pan-RAF and MEK Inhibitors in NRAS Mutant Melanoma,” Molecular Cancer 14 (2015): 27.

[189] G. A. Nishiguchi, A. Rico, H. Tanner, et al., “Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers,” Journal of Medicinal Chemistry 60 (2017): 4869–4881.

[190] W. Shao, Y. M. Mishina, Y. Feng, et al., “Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF,” Cancer Research 78 (2018): 1537–1548.

[191] K. Honda, N. Yamamoto, H. Nokihara, et al., “Phase I and Pharmacokinetic/Pharmacodynamic Study of RO5126766, a First-in-class Dual Raf/MEK Inhibitor, in Japanese Patients With Advanced Solid Tumors,” Cancer Chemotherapy and Pharmacology 72 (2013): 577–584.

[192] M. Martinez-Garcia, U. Banerji, J. Albanell, et al., “First-in-human, Phase I Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-class Dual MEK/RAF Inhibitor in Patients With Solid Tumors,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 18 (2012): 4806–4819.

[193] C. Guo, M. Chénard-Poirier, D. Roda, et al., “Intermittent Schedules of the Oral RAF-MEK Inhibitor CH5126766/VS-6766 in Patients With RAS/RAF-mutant Solid Tumours and Multiple Myeloma: A Single-centre, Open-label, Phase 1 Dose-escalation and Basket Dose-expansion Study,” The Lancet Oncology 21 (2020): 1478–1488.

[194] M. Wada, M. Horinaka, T. Yamazaki, N. Katoh, and T. Sakai, “The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May be a Potential Therapy for RAS-mutated Tumor Cells,” PLoS ONE 9 (2014): e113217.

[195] R. J. Sullivan, J. R. Infante, F. Janku, et al., “First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients With MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study,” Cancer Discovery 8 (2018): 184–195.

[196] G. Hatzivassiliou, B. Liu, C. O'Brien, et al., “ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors,” Molecular Cancer Therapeutics 11 (2012): 1143–1154.

[197] E. J. Morris, S. Jha, C. R. Restaino, et al., “Discovery of a Novel ERK Inhibitor With Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors,” Cancer Discovery 3 (2013): 742–750.

[198] M. S. Carlino, J. R. Todd, K. Gowrishankar, et al., “Differential Activity of MEK and ERK Inhibitors in BRAF Inhibitor Resistant Melanoma,” Molecular Oncology 8 (2014): 544–554.

[199] C. Krepler, M. Xiao, K. Sproesser, et al., “Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22 (2016): 1592–1602.

[200] L. G. Ahronian, E. M. Sennott, E. M. Van Allen, et al., “Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer Through MAPK Pathway Alterations,” Cancer Discovery 5 (2015): 358–367.

[201] U. A. Germann, B. F. Furey, W. Markland, et al., “Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity With the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib),” Molecular Cancer Therapeutics 16, no. 11 (2017): 2351–2363.

[202] B. Mendzelevski, G. Ferber, F. Janku, et al., “Effect of Ulixertinib, a Novel ERK1/2 Inhibitor, on the QT/QTc Interval in Patients With Advanced Solid Tumor Malignancies,” Cancer Chemotherapy and Pharmacology 81 (2018): 1129–1141.

[203] J. Wu, D. Liu, M. Offin, et al., “Characterization and Management of ERK Inhibitor Associated Dermatologic Adverse Events: Analysis From a Nonrandomized Trial of ulixertinib for Advanced Cancers,” Investigational New Drugs 39 (2021): 785–795.

[204] E. I. Buchbinder, J. V. Cohen, G. Tarantino, et al., “A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma,” Cancer Research Communications 4 (2024): 1321–1327.

[205] A. Varga, J. Soria, A. Hollebecque, et al., “A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients With Advanced Solid Tumors,” Clinical Cancer Research: An Official Journal of the 26 (2020): 1229–1236.

[206] M. Merchant, J. Moffat, G. Schaefer, et al., “Combined MEK and ERK Inhibition Overcomes Therapy-mediated Pathway Reactivation in RAS Mutant Tumors,” PLoS ONE 12 (2017): e0185862.

[207] D. J. Wong, L. Robert, M. S. Atefi, et al., “Antitumor Activity of the ERK Inhibitor SCH772984 [corrected] Against BRAF Mutant, NRAS Mutant and Wild-type Melanoma,” Molecular Cancer 13 (2014): 194.

[208] A. Stathis, A. W. Tolcher, and J. S. Wang, “Results of an Open-label Phase 1b Study of the ERK Inhibitor MK-8353 plus the MEK Inhibitor selumetinib in Patients With Advanced or Metastatic Solid Tumors,” Investigational New Drugs 41 (2023): 380–390.

[209] C. Weekes, A. Lockhart, P. LoRusso, et al., “A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination With the ERK1/2 Inhibitor GDC-0994 in Patients With Advanced Solid Tumors,” The Oncologist 25 (2020): 833–e1438.

[210] H. Ray-David, Y. Romeo, G. Lavoie, et al., “RSK Promotes G2 DNA Damage Checkpoint Silencing and Participates in Melanoma Chemoresistance,” Oncogene 32 (2013): 4480–4489.

[211] M. R. Pambid, R. Berns, H. H. Adomat, et al., “Overcoming Resistance to Sonic Hedgehog Inhibition by Targeting p90 Ribosomal S6 Kinase in Pediatric Medulloblastoma,” Pediatric Blood & Cancer 61 (2014): 107–115.

[212] R. Jain, M. Mathur, J. Lan, et al., “Discovery of Potent and Selective RSK Inhibitors as Biological Probes,” Journal of Medicinal Chemistry 58 (2015): 6766–6783.

[213] E. B. Wright and D. A. Lannigan, “Therapeutic Targeting of p90 Ribosomal S6 Kinase,” Frontiers in Cell and Developmental Biology 11 (2023): 1297292.

[214] C. Kosnopfel, S. Wendlinger, H. Niessner, et al., “Inhibition of p90 Ribosomal S6 Kinases Disrupts Melanoma Cell Growth and Immune Evasion,” Journal of Experimental & Clinical Cancer Research: CR 42 (2023): 175.

[215] A. W. Tolcher, W. Peng, and E. Calvo, “Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors,” Molecular Cancer Therapeutics 17 (2018): 3–16.

[216] E. Jokinen and J. P. Koivunen, “MEK and PI3K Inhibition in Solid Tumors: Rationale and Evidence to Date,” Therapeutic Advances in Medical Oncology 7 (2015): 170–180.

[217] S. Jean and A. A. Kiger, “Classes of Phosphoinositide 3-kinases at a Glance,” Journal of Cell Science 127 (2014): 923–928.

[218] M. C. de Gooijer, P. Zhang, L. C. M. Buil, et al., “Buparlisib Is a Brain Penetrable Pan-PI3K Inhibitor,” Scientific Reports 8 (2018): 10784.

[219] T. Amaral, H. Niessner, T. Sinnberg, et al., “An Open-label, Single-arm, Phase II Trial of buparlisib in Patients With Melanoma Brain Metastases Not Eligible for Surgery or Radiosurgery-the BUMPER Study,” Neuro-Oncology Advances 2 (2020): vdaa140.

[220] S. Nymark Aasen, H. Parajuli, T. Hoang, et al., “Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors,” International Journal of Molecular Sciences 20, no. 17 (2019): 4235.

[221] D. Sarker, J. E. Ang, R. Baird, et al., “First-in-human Phase I Study of pictilisib (GDC-0941), a Potent Pan-class I Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Patients With Advanced Solid Tumors,” Clinical Cancer Research: An Official Journal of the 21 (2015): 77–86.

[222] M. K. Kiessling, A. Curioni-Fontecedro, P. Samaras, et al., “Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma,” PLoS ONE 11 (2016): e0147682.

[223] B. Wei, S. B. Hoover, C. J. Peer, et al., “Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma,” Molecular Cancer Therapeutics 19 (2020): 2308–2318.

[224] B. Wei, H. T. Michael, C. H. Halsey, et al., “Synergistic Targeted Inhibition of MEK and Dual PI3K/mTOR Diminishes Viability and Inhibits Tumor Growth of Canine Melanoma Underscoring Its Utility as a Preclinical Model for human Mucosal Melanoma,” Pigment Cell & Melanoma Research 29 (2016): 643–655.

[225] P. L. Bedard, J. Tabernero, F. Janku, et al., “A Phase Ib Dose-escalation Study of the Oral Pan-PI3K Inhibitor buparlisib (BKM120) in Combination With the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients With Selected Advanced Solid Tumors,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21 (2015): 730–738.

[226] A. Bardia, M. Gounder, J. Rodon, et al., “Phase Ib Study of Combination Therapy With MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients With Advanced Solid Tumors With RAS/RAF Alterations,” The Oncologist 25 (2020): e160–e169.

[227] G. I. Shapiro, P. LoRusso, E. Kwak, et al., “Phase Ib Study of the MEK Inhibitor cobimetinib (GDC-0973) in Combination With the PI3K Inhibitor pictilisib (GDC-0941) in Patients With Advanced Solid Tumors,” Investigational New Drugs 38 (2020): 419–432.

[228] C. Garcia-Echeverria and W. R. Sellers, “Drug Discovery Approaches Targeting the PI3K/Akt Pathway in Cancer,” Oncogene 27 (2008): 5511–5526.

[229] D. Ciołczyk-Wierzbicka, A. Krawczyk, M. Zarzycka, G. Zemanek, and K. Wierzbicki, “Three Generations of mTOR Kinase Inhibitors in the Activation of the Apoptosis Process in Melanoma Cells,” Journal of Cell Communication and Signaling 17 (2023): 975–989.

[230] J. E. Grilley-Olson, P. L. Bedard, A. Fasolo, et al., “A Phase Ib Dose-escalation Study of the MEK Inhibitor Trametinib in Combination With the PI3K/mTOR Inhibitor GSK2126458 in Patients With Advanced Solid Tumors,” Investigational New Drugs 34 (2016): 740–749.

[231] A. M. Schram, L. Gandhi, M. M. Mita, et al., “A Phase Ib Dose-escalation and Expansion Study of the Oral MEK Inhibitor pimasertib and PI3K/MTOR Inhibitor voxtalisib in Patients With Advanced Solid Tumours,” British Journal of Cancer 119 (2018): 1471–1476.

[232] J. A. Engelman, “Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations,” Nature Reviews Cancer 9 (2009): 550–562.

[233] D. Morgensztern and H. L. McLeod, “PI3K/Akt/mTOR Pathway as a Target for Cancer Therapy,” Anti-Cancer Drugs 16 (2005): 797–803.

[234] D. A. Kircher, K. A. Trombetti, M. R. Silvis, et al., “AKT1(E17K) Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis,” Molecular Cancer Research: MCR 17 (2019): 1787–1800.

[235] Y. Feng, E. Lau, M. Scortegagna, et al., “Inhibition of Melanoma Development in the Nras((Q61K))::Ink4a(-/-) Mouse Model by the Small Molecule BI-69A11,” Pigment Cell & Melanoma Research 26 (2013): 136–142.

[236] M. Forino, D. Jung, J. B. Easton, P. J. Houghton, and M. Pellecchia, “Virtual Docking Approaches to Protein Kinase B Inhibition,” Journal of Medicinal Chemistry 48 (2005): 2278–2281.

[237] C. Aghajanian, K. M. Bell-McGuinn, H. A. Burris, et al., “A Phase I, Open-label, Two-stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Patients With Solid Tumors,” Investigational New Drugs 36 (2018): 1016–1025.

[238] M. Dumble, M. Crouthamel, S. Zhang, et al., “Discovery of Novel AKT Inhibitors With Enhanced Anti-tumor Effects in Combination With the MEK Inhibitor,” PLoS ONE 9 (2014): e100880.

[239] T. A. Yap, L. Yan, A. Patnaik, et al., “First-in-man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29 (2011): 4688–4695.

[240] J. C. Bendell, J. Rodon, H. A. Burris, et al., “Phase I, Dose-escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 30 (2012): 282–290.

[241] J. Rodon, I. Braña, L. L. Siu, et al., “Phase I Dose-escalation and -expansion Study of buparlisib (BKM120), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors,” Investigational New Drugs 32 (2014): 670–681.

[242] Y. Wu, L. Zhang, L. Trandafir, et al., “Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors,” AntiCancer Research 36 (2016): 6185–6194.

[243] V. Petit, J. Raymond, C. Alberti, et al., “C57BL/6 congenic Mouse NRAS(Q61K) Melanoma Cell Lines Are Highly Sensitive to the Combination of Mek and Akt Inhibitors in Vitro and in Vivo,” Pigment Cell & Melanoma Research 32 (2019): 829–841.

[244] J. F. Liu, K. P. Gray, A. A. Wright, et al., “Results From a Single Arm, Single Stage Phase II Trial of Trametinib and GSK2141795 in Persistent or Recurrent Cervical Cancer,” Gynecologic Oncology 154 (2019): 95–101.

[245] A. W. Tolcher, R. Kurzrock, V. Valero, et al., “Phase I Dose-escalation Trial of the Oral AKT Inhibitor uprosertib in Combination With the Oral MEK1/MEK2 Inhibitor Trametinib in Patients With Solid Tumors,” Cancer Chemotherapy and Pharmacology 85 (2020): 673–683.

[246] A. W. Tolcher, A. Patnaik, K. P. Papadopoulos, et al., “Phase I Study of the MEK Inhibitor trametinib in Combination With the AKT Inhibitor afuresertib in Patients With Solid Tumors and Multiple Myeloma,” Cancer Chemotherapy and Pharmacology 75 (2015): 183–189.

[247] B. K. Ragon, O. Odenike, M. R. Baer, et al., “Oral MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Patients with Acute Myeloid Leukemia with RAS Mutations: A Phase II Study,” Clinical Lymphoma, Myeloma & Leukemia 19 (2019): 431–440.e413.

[248] A. P. Algazi, R. Esteve-Puig, A. Nosrati, et al., “Dual MEK/AKT Inhibition With Trametinib and GSK2141795 Does Not Yield Clinical Benefit in Metastatic NRAS-mutant and Wild-type Melanoma,” Pigment Cell & Melanoma Research 31 (2018): 110–114.

[249] M. Shimobayashi and M. N. Hall, “Making New Contacts: The mTOR Network in Metabolism and Signalling Crosstalk. Nature Reviews,” Molecular Cell Biology 15 (2014): 155–162.

[250] F. Conciatori, C. Bazzichetto, I. Falcone, et al., “Role of mTOR Signaling in Tumor Microenvironment: An Overview,” International Journal of Molecular Sciences 19, no. 8 (2018): 2453.

[251] D. Ciołczyk-Wierzbicka, D. Gil, and P. Laidler, “Treatment of Melanoma With Selected Inhibitors of Signaling Kinases Effectively Reduces Proliferation and Induces Expression of Cell Cycle Inhibitors,” Medical Oncology (Northwood, London, England) 35 (2017): 7.

[252] D. Ciołczyk-Wierzbicka, D. Gil, M. Zarzycka, and P. Laidler, “mTOR Inhibitor everolimus Reduces Invasiveness of Melanoma Cells,” Human Cell 33 (2020): 88–97.

[253] K. E. O'Reilly, F. Rojo, Q. She, et al., “mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt,” Cancer Research 66 (2006): 1500–1508.

[254] A. Tolcher, J. Bendell, K. Papadopoulos, et al., “A Phase IB Trial of the Oral MEK Inhibitor trametinib (GSK1120212) in Combination With everolimus in Patients With Advanced Solid Tumors,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 26 (2015): 58–64.

[255] M. Mita, S. Fu, S. A. Piha-Paul, et al., “Phase I Trial of MEK 1/2 Inhibitor pimasertib Combined With mTOR Inhibitor temsirolimus in Patients With Advanced Solid Tumors,” Investigational New Drugs 35 (2017): 616–626.

[256] J. R. Bayascas, “PDK1: The Major Transducer of PI 3-kinase Actions,” Current Topics in Microbiology and Immunology 346 (2010): 9–29.

[257] L. R. Pearce, D. Komander, and D. R. Alessi, “The Nuts and Bolts of AGC Protein Kinases,” Nature Reviews Molecular Cell Biology 11 (2010): 9–22.

[258] C. Raimondi, A. Chikh, A. P. Wheeler, T. Maffucci, and M. Falasca, “A Novel Regulatory Mechanism Links PLCγ1 to PDK1,” Journal of Cell Science 125 (2012): 3153–3163.

[259] W. Cai, M. Q. Nguyen, N. A. Wilski, et al., “A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma,” Cancer Research 82 (2022): 2625–2639.

[260] D. M. Miller and K. T. Flaherty, “Cyclin-dependent Kinases as Therapeutic Targets in Melanoma,” Pigment Cell & Melanoma Research 27 (2014): 351–365.

[261] A. Patnaik, L. S. Rosen, S. M. Tolaney, et al., “Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients With Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors,” Cancer Discovery 6 (2016): 740–753.

[262] E. Hamilton, J. Cortes, O. Ozyilkan, et al., “nextMONARCH: Abemaciclib Monotherapy or Combined with Tamoxifen for Metastatic Breast Cancer,” Clinical Breast Cancer 21 (2021): 181–190.e182.

[263] N. C. Turner, J. Ro, F. André, et al., “Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer,” The New England Journal of Medicine 373 (2015): 209–219.

[264] S. Loibl, F. Marmé, M. Martin, et al., “Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39 (2021): 1518–1530.

[265] G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, et al., “Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer,” The New England Journal of Medicine 375 (2016): 1738–1748.

[266] S. Im, Y. Lu, A. Bardia, et al., “Overall Survival With Ribociclib plus Endocrine Therapy in Breast Cancer,” The New England Journal of Medicine 381 (2019): 307–316.

[267] C. M. van Herpen, S. S. Agarwala, A. Hauschild, H. Nauwelaerts, A. Zubel, and R. Dummer, “Biomarker Results From a Phase II Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS- or BRAF-mutated Melanoma,” Oncotarget 10 (2019): 1850–1859.

[268] J. Zhou, S. Zhang, X. Chen, et al., “Palbociclib, a Selective CDK4/6 Inhibitor, Enhances the Effect of Selumetinib in RAS-driven Non-small Cell Lung Cancer,” Cancer Letters 408 (2017): 130–137.

[269] Z. Tao, J. M. Le Blanc, C. Wang, et al., “Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers in Vitro and in Vivo,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22 (2016): 122–133.

[270] V. Yadav, T. F. Burke, L. Huber, et al., “The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting From MAPK Reactivation and Cyclin D1 Upregulation,” Molecular Cancer Therapeutics 13 (2014): 2253–2263.

[271] C. Posch, M. Sanlorenzo, J. Ma, S. T. Kim, M. Zekhtser, and S. Ortiz-Urda, “MEK/CDK4,6 co-targeting Is Effective in a Subset of NRAS, BRAF and ‘Wild Type’ melanomas,” Oncotarget 9 (2018): 34990–34995.

[272] J. L. Teh, P. F. Cheng, T. J. Purwin, et al., “In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms,” Cancer Discovery 8 (2018): 568–581.

[273] L. N. Kwong, J. C. Costello, H. Liu, et al., “Oncogenic NRAS Signaling Differentially Regulates Survival and Proliferation in Melanoma,” Nature Medicine 18 (2012): 1503–1510.

[274] T. K. Hayes, F. Luo, O. Cohen, et al., “A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma,” Cancer Research 79 (2019): 2352–2366.

[275] S. Chen, X. Gong, Y. Zhang, et al., “RAF Inhibitor LY3009120 Sensitizes RAS or BRAF Mutant Cancer to CDK4/6 Inhibition by Abemaciclib via Superior Inhibition of Phospho-RB and Suppression of Cyclin D1,” Oncogene 37 (2018): 821–832.

[276] B. Louveau, M. Resche-Rigon, T. Lesimple, et al., “Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF (V600MUT) Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism,” Clinical Cancer Research: An Official Journal of the 27 (2021): 3876–3883.

[277] M. Schuler, L. Zimmer, K. B. Kim, et al., “Phase Ib/II Trial of Ribociclib in Combination With Binimetinib in Patients With NRAS-mutant Melanoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 28 (2022): 3002–3010.

[278] M. R. Webster, M. E. Fane, G. M. Alicea, et al., “Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma,” Molecular Cell 77 (2020): 633–644.e635.

[279] J. Canon, T. Osgood, S. H. Olson, et al., “The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents,” Molecular Cancer Therapeutics 14 (2015): 649–658.

[280] W. L. Gluck, M. M. Gounder, R. Frank, et al., “Phase 1 Study of the MDM2 Inhibitor AMG 232 in Patients With Advanced P53 Wild-type Solid Tumors or Multiple Myeloma,” Investigational New Drugs 38 (2020): 831–843.

[281] H. P. Erba, P. S. Becker, P. J. Shami, et al., “Phase 1b Study of the MDM2 Inhibitor AMG 232 With or Without Trametinib in Relapsed/Refractory Acute Myeloid Leukemia,” Blood Advances 3 (2019): 1939–1949.

[282] S. J. Moschos, S. Sandhu, K. D. Lewis, et al., “Targeting Wild-type TP53 Using AMG 232 in Combination With MAPK Inhibition in Metastatic Melanoma; a Phase 1 Study,” Investigational New Drugs 40 (2022): 1051–1065.

[283] Y. Liu, M. Xie, T. Song, H. Sheng, X. Yu, and Z. Zhang, “A Novel BH3 Mimetic Efficiently Induces Apoptosis in Melanoma Cells Through Direct Binding to Anti-apoptotic Bcl-2 family Proteins, Including Phosphorylated Mcl-1,” Pigment Cell & Melanoma Research 28 (2015): 161–170.

[284] Y. F. Wang, C. C. Jiang, K. A. Kiejda, S. Gillespie, X. D. Zhang, and P. Hersey, “Apoptosis Induction in human Melanoma Cells by Inhibition of MEK Is Caspase-independent and Mediated by the Bcl-2 family Members PUMA, Bim, and Mcl-1,” Clinical Cancer Research: An Official Journal of the 13 (2007): 4934–4942.

[285] K. J. Basile and A. E. Aplin, “Downregulation of Noxa by RAF/MEK Inhibition Counteracts Cell Death Response in Mutant B-RAF Melanoma Cells,” American Journal of Cancer Research 2 (2012): 726–735.

[286] D. Decaudin, E. Frisch Dit Leitz, F. Nemati, et al., “Preclinical Evaluation of Drug Combinations Identifies co-inhibition of Bcl-2/XL/W and MDM2 as a Potential Therapy in Uveal Melanoma,” European Journal of Cancer (Oxford, England: 1990) 126 (2020): 93–103.

[287] C. Posch, B. D. Cholewa, I. Vujic, et al., “Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma,” The Journal of Investigative Dermatology 135 (2015): 2475–2483.

[288] H. A. Lane and E. A. Nigg, “Antibody Microinjection Reveals an Essential Role for human Polo-Like Kinase 1 (Plk1) in the Functional Maturation of Mitotic Centrosomes,” The Journal of Cell Biology 135 (1996): 1701–1713.

[289] A. Jalili, A. Moser, M. Pashenkov, et al., “Polo-Like Kinase 1 Is a Potential Therapeutic Target in human Melanoma,” The Journal of Investigative Dermatology 131 (2011): 1886–1895.

[290] H. Y. Chen and J. Villanueva, “Playing Polo-Like Kinase in NRAS-Mutant Melanoma,” The Journal of Investigative Dermatology 135 (2015): 2352–2355.

[291] C. Vardabasso, A. Gaspar-Maia, D. Hasson, et al., “Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma,” Molecular Cell 59 (2015): 75–88.

[292] L. Paoluzzi, D. Hanniford, E. Sokolova, et al., “BET and BRAF Inhibitors Act Synergistically Against BRAF-mutant Melanoma,” Cancer Medicine 5 (2016): 1183–1193.

[293] M. Tiago, C. Capparelli, D. A. Erkes, et al., “Targeting BRD/BET Proteins Inhibits Adaptive Kinome Upregulation and Enhances the Effects of BRAF/MEK Inhibitors in Melanoma,” British Journal of Cancer 122 (2020): 789–800.

[294] M. F. Segura, B. Fontanals-Cirera, A. Gaziel-Sovran, et al., “BRD4 sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy,” Cancer Research 73 (2013): 6264–6276.

[295] I. M. Echevarría-Vargas, P. I. Reyes-Uribe, A. N. Guterres, et al., “Co-targeting BET and MEK as Salvage Therapy for MAPK and Checkpoint Inhibitor-resistant Melanoma,” EMBO Molecular Medicine 10, no. 5 (2018): e8446.

[296] M. Ameratunga, I. Braña, P. Bono, et al., “First-in-human Phase 1 Open Label Study of the BET Inhibitor ODM-207 in Patients With Selected Solid Tumours,” British Journal of Cancer 123 (2020): 1730–1736.

[297] S. A. Piha-Paul, J. C. Sachdev, M. Barve, et al., “First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients With Relapsed/Refractory Solid Tumors,” Clinical Cancer Research: An Official Journal of the 25 (2019): 6309–6319.

[298] M. Drzewiecka, A. Gajos-Michniewicz, G. Hoser, et al., “Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor,” Genes 14, no. 6 (2023): 1295.

[299] M. Haberland, R. L. Montgomery, and E. N. Olson, “The Many Roles of Histone Deacetylases in Development and Physiology: Implications for Disease and Therapy,” Nature Reviews Genetics 10 (2009): 32–42.

[300] N. Ibrahim, E. I. Buchbinder, S. R. Granter, et al., “A Phase I Trial of panobinostat (LBH589) in Patients With Metastatic Melanoma,” Cancer Medicine 5 (2016): 3041–3050.

[301] O. Maertens, R. Kuzmickas, H. E. Manchester, et al., “MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas,” Cancer Discovery 9, no. 4 (2019): 526–545.

[302] F. Faião-Flores, M. F. Emmons, M. A. Durante, et al., “HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25 (2019): 5686–5701.

[303] M. Chao, L. Chang, H. Tu, et al., “Combination Treatment Strategy for Pancreatic Cancer Involving the Novel HDAC Inhibitor MPT0E028 With a MEK Inhibitor Beyond K-Ras Status,” Clinical Epigenetics 11 (2019): 85.

[304] J. R. Diamond, T. M. Pitts, D. Ungermannova, et al., “Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors,” Molecular Cancer Therapeutics 21 (2022): 397–406.

[305] X. Wang, B. C. Waschke, R. A. Woolaver, et al., “Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas,” Cancer Immunology Research 7 (2019): 1318–1331.

[306] A. R. Schreiber, J. A. Kagihara, B. R. Corr, et al., “First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients With Advanced Solid Tumors,” Cancers 16, no. 1 (2023): 91.

[307] C. J. Terranova, “Chromatin state Profiling Reveals PRC2 Inhibition as a Therapeutic Target in NRAS-mutant Melanoma,” Molecular & Cellular Oncology 8 (2021): 1986350.

[308] S. Fujii, K. Tokita, N. Wada, et al., “MEK-ERK Pathway Regulates EZH2 Overexpression in Association With Aggressive Breast Cancer Subtypes,” Oncogene 30 (2011): 4118–4128.

[309] Y. Wang, N. Hou, X. Cheng, et al., “Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma,” International Journal of Biological Sciences 13 (2017): 652–659.

[310] E. Riquelme, C. Behrens, H. Y. Lin, et al., “Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations,” Cancer Research 76 (2016): 675–685.

[311] C. J. Terranova, M. Tang, M. Maitituoheti, et al., “Reprogramming of Bivalent Chromatin States in NRAS Mutant Melanoma Suggests PRC2 Inhibition as a Therapeutic Strategy,” Cell Reports 36 (2021): 109410.

[312] A. J. Lakhter, R. P. Sahu, Y. Sun, et al., “Chloroquine Promotes Apoptosis in Melanoma Cells by Inhibiting BH3 Domain-mediated PUMA Degradation,” The Journal of Investigative Dermatology 133 (2013): 2247–2254.

[313] E. H. Baehrecke, “Autophagy: Dual Roles in Life and Death?,” Nature Reviews Molecular Cell Biology 6 (2005): 505–510.

[314] J. E. Chipuk, J. C. Fisher, C. P. Dillon, R. W. Kriwacki, T. Kuwana, and D. R. Green, “Mechanism of Apoptosis Induction by Inhibition of the Anti-apoptotic BCL-2 Proteins,” Proceedings of the National Academy of Sciences of the United States of America 105 (2008): 20327–20332.

[315] C. G. Kinsey, S. A. Camolotto, A. M. Boespflug, et al., “Protective Autophagy Elicited by RAF→MEK→ERK Inhibition Suggests a Treatment Strategy for RAS-driven Cancers,” Nature Medicine 25 (2019): 620–627.

[316] J. Jandova, S. L. Park, M. J. Corenblum, et al., “Mefloquine Induces ER Stress and Apoptosis in BRAFi-resistant A375-BRAF(V600E) /NRAS(Q61K) Malignant Melanoma Cells Targeting Intracranial Tumors in a Bioluminescent Murine Model,” Molecular Carcinogenesis 61 (2022): 603–614.

[317] G. Awada, J. K. Schwarze, J. Tijtgat, G. Fasolino, V. Kruse, and B. Neyns, “A Lead-in Safety Study Followed by a Phase 2 Clinical Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Advanced BRAFV600 Mutant Melanoma Patients Previously Treated With BRAF-/MEK-inhibitors and Immune Checkpoint Inhibitors,” Melanoma Research 32 (2022): 183–191.

[318] J. M. Mehnert, T. C. Mitchell, A. C. Huang, et al., “BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma,” Clinical Cancer Research: An Official Journal of the 28 (2022): 1098–1106.

[319] A. R. Hess and M. J. Hendrix, “Focal Adhesion Kinase Signaling and the Aggressive Melanoma Phenotype,” Cell Cycle (Georgetown, Tex) 5 (2006): 478–480.

[320] G. W. McLean, N. O. Carragher, E. Avizienyte, J. Evans, V. G. Brunton, and M. C. Frame, “The Role of Focal-adhesion Kinase in Cancer—a New Therapeutic Opportunity,” Nature Reviews Cancer 5 (2005): 505–515.

[321] A. Mousson, M. Legrand, T. Steffan, et al., “Inhibiting FAK-Paxillin Interaction Reduces Migration and Invadopodia-Mediated Matrix Degradation in Metastatic Melanoma Cells,” Cancers 13, no. 8 (2021): 1871.

[322] H. Hu, S. Wang, H. Shang, et al., “Roles and Inhibitors of FAK in Cancer: Current Advances and Future Directions,” Frontiers in Pharmacology 15 (2024): 1274209.

[323] S. Shao, L. Piao, J. Wang, et al., “Tspan9 Induces EMT and Promotes Osteosarcoma Metastasis via Activating FAK-Ras-ERK1/2 Pathway,” Frontiers in Oncology 12 (2022): 774988.

[324] G. Mak, J. Soria, S. P. Blagden, et al., “A Phase Ib Dose-finding, Pharmacokinetic Study of the Focal Adhesion Kinase Inhibitor GSK2256098 and Trametinib in Patients With Advanced Solid Tumours,” British Journal of Cancer 120 (2019): 975–981.

[325] J. Zhao, C. Galvez, K. E. Beckermann, D. B. Johnson, and J. A. Sosman, “Novel Insights Into the Pathogenesis and Treatment of NRAS Mutant Melanoma,” Expert Review of Precision Medicine and Drug Development 6 (2021): 281–294.

[326] J. Delyon, A. Servy, F. Laugier, et al., “PDE4D promotes FAK-mediated Cell Invasion in BRAF-mutated Melanoma,” Oncogene 36 (2017): 3252–3262.

[327] B. Louveau, et al., “Combined PDE4+MEK Inhibition Shows Antiproliferative Effects in NRASQ61 Mutated Melanoma Preclinical Models,” Melanoma Research 34 (2023): 186-192, https://doi.org/10.1097/cmr.0000000000000950.

[328] U. Eskiocak, V. Ramesh, J. G. Gill, et al., “Synergistic Effects of Ion Transporter and MAP Kinase Pathway Inhibitors in Melanoma,” Nature Communications 7 (2016): 12336.

[329] A. E. Frankel, U. Eskiocak, J. G. Gill, et al., “Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients,” Neoplasia (New York, NY) 19 (2017): 255–260.

[330] T. Mukhopadhyay, J. Sasaki, R. Ramesh, and J. A. Roth, “Mebendazole Elicits a Potent Antitumor Effect on human Cancer Cell Lines both in Vitro and in Vivo,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 8 (2002): 2963–2969.

[331] C. M. Simbulan-Rosenthal, S. Dakshanamurthy, A. Gaur, et al., “The Repurposed Anthelmintic Mebendazole in Combination With Trametinib Suppresses Refractory NRASQ61K Melanoma,” Oncotarget 8 (2017): 12576–12595.

[332] N. Coupe, P. Corrie, M. Hategan, et al., “PACMEL: A Phase 1 Dose Escalation Trial of trametinib (GSK1120212) in Combination With paclitaxel,” European Journal of Cancer (Oxford, England: 1990) 51 (2015): 359–366.

[333] A. Gupta, S. Love, A. Schuh, et al., “DOC-MEK: A Double-blind Randomized Phase II Trial of docetaxel With or Without Selumetinib in Wild-type BRAF Advanced Melanoma,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 25 (2014): 968–974.

[334] B. H. Burmeister, M. A. Henderson, J. Ainslie, et al., “Adjuvant Radiotherapy versus Observation Alone for Patients at Risk of Lymph-node Field Relapse After Therapeutic Lymphadenectomy for Melanoma: A Randomised Trial,” The Lancet Oncology 13 (2012): 589–597.

[335] M. A. Henderson, B. H. Burmeister, J. Ainslie, et al., “Adjuvant Lymph-node Field Radiotherapy versus Observation Only in Patients With Melanoma at High Risk of Further Lymph-node Field Relapse After Lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year Follow-up of a Phase 3, Randomised Controlled Trial,” The Lancet Oncology 16 (2015): 1049–1060.

[336] R. Manon, A. O'Neill, J. Knisely, et al., “Phase II Trial of Radiosurgery for One to Three Newly Diagnosed Brain Metastases From Renal Cell Carcinoma, Melanoma, and Sarcoma: An Eastern Cooperative Oncology Group Study (E 6397),” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23 (2005): 8870–8876.

[337] J. A. Bonner, B. T. Vroman, T. J. Christianson, and L. M. Karnitz, “Ionizing Radiation-induced MEK and Erk Activation Does Not Enhance Survival of Irradiated human Squamous Carcinoma Cells,” International Journal of Radiation Oncology, Biology, Physics 42 (1998): 921–925.

[338] J. Pomp, I. J. M. Ouwerkerk, J. Hermans, et al., “The Influence of the Oncogenes NRAS and MYC on the Radiation Sensitivity of Cells of a human Melanoma Cell Line,” Radiation Research 146 (1996): 374–381.

[339] E. J. Bernhard, E. J. Stanbridge, S. Gupta, et al., “Direct Evidence for the Contribution of Activated N-ras and K-ras Oncogenes to Increased Intrinsic Radiation Resistance in human Tumor Cell Lines,” Cancer Research 60, no. 23 (2000): 6597–6600.

[340] E. J. Chung, A. P. Brown, H. Asano, et al., “In Vitro and in Vivo Radiosensitization With AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15 (2009): 3050–3057.

[341] A. M. Shannon, B. A. Telfer, P. D. Smith, et al., “The Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 15 (2009): 6619–6629.

[342] U. Schick, J. Kyula, H. Barker, et al., “Trametinib Radiosensitises RAS- and BRAF-mutated Melanoma by Perturbing Cell Cycle and Inducing Senescence,” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 117 (2015): 364–375.

[343] A. L. Ho, R. K. Grewal, R. Leboeuf, et al., “Selumetinib-enhanced Radioiodine Uptake in Advanced Thyroid Cancer,” The New England Journal of Medicine 368 (2013): 623–632.

[344] K. McGrail, P. Granado-Martínez, R. Esteve-Puig, et al., “BRAF Activation by Metabolic Stress Promotes Glycolysis Sensitizing NRAS(Q61)-mutated Melanomas to Targeted Therapy,” Nature Communications 13 (2022): 7113.

[345] R. Bartrons, H. Simon-Molas, A. Rodríguez-García, et al., “Fructose 2,6-Bisphosphate in Cancer Cell Metabolism,” Frontiers in Oncology 8 (2018): 331.

[346] A. Sharma, N. R. Trivedi, M. A. Zimmerman, D. A. Tuveson, C. D. Smith, and G. P. Robertson, “Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors,” Cancer Research 65 (2005): 2412–2421.

[347] K. T. Flaherty, J. Schiller, L. M. Schuchter, et al., “A Phase I Trial of the Oral, Multikinase Inhibitor sorafenib in Combination With Carboplatin and paclitaxel,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 14 (2008): 4836–4842.

[348] T. Eisen, T. Ahmad, K. T. Flaherty, et al., “Sorafenib in Advanced Melanoma: A Phase II Randomised Discontinuation Trial Analysis,” British Journal of Cancer 95 (2006): 581–586.

[349] P. A. Ott, A. Hamilton, C. Min, et al., “A Phase II Trial of sorafenib in Metastatic Melanoma With Tissue Correlates,” PLoS ONE 5 (2010): e15588.

[350] M. A. Wilson, F. Zhao, R. Letrero, et al., “Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated With Carboplatin, Paclitaxel, and sorafenib,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 20 (2014): 3328–3337.

[351] I. V. Fedorenko, B. Fang, J. M. Koomen, G. T. Gibney, and K. S. Smalley, “Amuvatinib Has Cytotoxic Effects Against NRAS-mutant Melanoma but Not BRAF-mutant Melanoma,” Melanoma Research 24 (2014): 448–453.

[352] C. J. Phillip, S. Zaman, S. Shentu, et al., “Targeting MET Kinase With the Small-molecule Inhibitor amuvatinib Induces Cytotoxicity in Primary Myeloma Cells and Cell Lines,” Journal of Hematology & Oncology 6 (2013): 92.

[353] J. Matsui, Y. Yamamoto, Y. Funahashi, et al., “E7080, a Novel Inhibitor That Targets Multiple Kinases, Has Potent Antitumor Activities Against Stem Cell Factor Producing human Small Cell Lung Cancer H146, Based on Angiogenesis Inhibition,” International Journal of Cancer 122 (2008): 664–671.

[354] J. Matsui, Y. Funahashi, T. Uenaka, T. Watanabe, A. Tsuruoka, and M. Asada, “Multi-kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-receptor (VEGF-R) 2 and VEGF-R3 Kinase,” Clinical Cancer Research: An Official Journal of the 14 (2008): 5459–5465.

[355] D. S. Hong, R. Kurzrock, G. S. Falchook, et al., “Phase 1b Study of lenvatinib (E7080) in Combination With Temozolomide for Treatment of Advanced Melanoma,” Oncotarget 6 (2015): 43127–43134.

[356] D. S. Hong, R. Kurzrock, J. J. Wheler, et al., “Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients With Advanced Solid Tumors and in an Expanded Cohort of Patients With Melanoma,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21 (2015): 4801–4810.

[357] G. Xu, P. O'Connell, D. Viskochil, et al., “The Neurofibromatosis Type 1 Gene Encodes a Protein Related to GAP,” Cell 62 (1990): 599–608.

[358] E. Hodis, I. Watson, G. Kryukov, et al., “A Landscape of Driver Mutations in Melanoma,” Cell 150 (2012): 251–263.

[359] M. Kiuru and K. J. Busam, “The NF1 Gene in Tumor Syndromes and Melanoma,” Laboratory Investigation 97 (2017):146–157.

[360] G. G. McGill, M. Horstmann, H. R. Widlund, et al., “Bcl2 regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability,” Cell 109 (2002): 707–718.

[361] L. A. Garraway, H. R. Widlund, M. A. Rubin, et al., “Integrative Genomic Analyses Identify MITF as a Lineage Survival Oncogene Amplified in Malignant Melanoma,” Nature 436 (2005): 117–122.

[362] J. Eberle and A. M. Hossini, “Expression and Function of Bcl-2 Proteins in Melanoma,” Current Genomics 9 (2008): 409–419.

[363] M. N. Serasinghe, D. J. Missert, J. J. Asciolla, et al., “Anti-apoptotic BCL-2 Proteins Govern Cellular Outcome Following B-RAF(V600E) Inhibition and Can be Targeted to Reduce Resistance,” Oncogene 34 (2015): 857–867.

[364] A. Najem, M. Krayem, F. Salès, et al., “P53 and MITF/Bcl-2 Identified as Key Pathways in the Acquired Resistance of NRAS-mutant Melanoma to MEK Inhibition,” European Journal of Cancer (Oxford, England: 1990) 83: 154–165.

[365] A. Gajos-Michniewicz and M. Czyz, “WNT Signaling in Melanoma,” International Journal of Molecular Sciences 21, no. 14 (2020): 4852.

[366] M. V. Semenov, R. Habas, B. T. Macdonald, and X. He, “SnapShot: Noncanonical Wnt Signaling Pathways,” Cell 131 (2007):1378.

[367] A. Gurney, F. Axelrod, C. J. Bond, et al., “Wnt Pathway Inhibition via the Targeting of Frizzled Receptors Results in Decreased Growth and Tumorigenicity of human Tumors,” Proceedings of the National Academy of Sciences of the United States of America 109 (2012): 11717–11722.

[368] T. Wiesner, J. He, R. Yelensky, et al., “Kinase Fusions Are Frequent in Spitz Tumours and Spitzoid Melanomas,” Nature Communications 5 (2014): 3116.

[369] I. Yeh, E. Jorgenson, L. Shen, et al., “Targeted Genomic Profiling of Acral Melanoma,” Journal of the National Cancer Institute 111 (2019): 1068–1077.

[370] C. Lezcano, A. N. Shoushtari, C. Ariyan, T. J. Hollmann, and K. J. Busam, “Primary and Metastatic Melanoma with NTRK Fusions,” American Journal of Surgical Pathology 42 (2018): 1052–1058.

[371] R. C. Doebele, A. Drilon, L. Paz-Ares, et al., “Entrectinib in Patients With Advanced or Metastatic NTRK Fusion-positive Solid Tumours: Integrated Analysis of Three Phase 1–2 Trials,” The Lancet Oncology 21 (2020): 271–282.

[372] A. Drilon, T. W. Laetsch, S. Kummar, et al., “Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children,” The New England Journal of Medicine 378 (2018): 731–739.

[373] J. Villanueva, J. Infante, C. Krepler, et al., “Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma,” Cell Reports 4 (2013): 1090–1099.

[374] M. Hoogstraat, C. G. Gadellaa-van Hooijdonk, I. Ubink, et al., “Detailed Imaging and Genetic Analysis Reveal a Secondary BRAF(L505H) Resistance Mutation and Extensive Intrapatient Heterogeneity in Metastatic BRAF Mutant Melanoma Patients Treated With vemurafenib,” Pigment Cell & Melanoma Research 28 (2015): 318–323.

[375] T. R. Wagenaar, L. Ma, B. Roscoe, S. M. Park, D. N. Bolon, and M. R. Green, “Resistance to Vemurafenib Resulting From a Novel Mutation in the BRAFV600E Kinase Domain,” Pigment Cell & Melanoma Research 27 (2014): 124–133.

[376] G. V. Long, C. Fung, A. M. Menzies, et al., “Increased MAPK Reactivation in Early Resistance to dabrafenib/trametinib Combination Therapy of BRAF-mutant Metastatic Melanoma,” Nature Communications 5 (2014): 5694.

[377] R. B. Corcoran, J. Settleman, and J. A. Engelman, “Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers,” Oncotarget 2 (2011): 336–346.

[378] A. Prahallad, C. Sun, S. Huang, et al., “Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR,” Nature 483 (2012): 100–103.

[379] M. Z. Mehdi, Z. M. Azar, and A. K. Srivastava, “Role of Receptor and Nonreceptor Protein Tyrosine Kinases in H2O2-induced PKB and ERK1/2 Signaling,” Cell Biochemistry and Biophysics 47 (2007): 1–10.

[380] R. Haq, J. Shoag, P. Andreu-Perez, et al., “Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF,” Cancer Cell 23 (2013): 302–315.

[381] O. M. Eichhoff, C. I. Stoffel, J. Käsler, et al., “ROS Induction Targets Persister Cancer Cells With Low Metabolic Activity in NRAS-Mutated Melanoma,” Cancer Research 83 (2023): 1128–1146.

[382] I. Tusa, S. Gagliardi, A. Tubita, et al., “ERK5 is Activated by Oncogenic BRAF and Promotes Melanoma Growth,” Oncogene 37 (2018): 2601–2614.

[383] B. A. Drew, M. E. Burow, and B. S. Beckman, “MEK5/ERK5 pathway: The First Fifteen Years,” Biochimica Et Biophysica Acta 1825 (2012): 37–48.

[384] S. J. Cook and P. A. Lochhead, “ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?,” Frontiers in Cell and Developmental Biology 10 (2022): 839997.

[385] C. Song, L. Wang, Q. Xu, et al., “Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma,” Scientific Reports 7 (2017): 46244.

[386] L. Benito-Jardón, M. Díaz-Martínez, N. Arellano-Sánchez, P. Vaquero-Morales, A. Esparís-Ogando, and J. Teixidó, “Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway,” Cancer Research 79 (2019): 2244–2256.

[387] C. Adam, L. Fusi, N. Weiss, et al., “Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways,” The Journal of Investigative Dermatology 140 (2020): 2455–2465.e2410.

[388] R. Possemato, K. M. Marks, Y. D. Shaul, et al., “Functional Genomics Reveal That the Serine Synthesis Pathway Is Essential in Breast Cancer,” Nature 476 (2011): 346–350.

[389] M. E. Pacold, K. R. Brimacombe, S. H. Chan, et al., “A PHGDH Inhibitor Reveals Coordination of Serine Synthesis and One-carbon Unit Fate,” Nature Chemical Biology 12 (2016): 452–458.

[390] Y. Ou, S. J. Wang, L. Jiang, B. Zheng, and W. Gu, “p53 Protein-mediated Regulation of Phosphoglycerate Dehydrogenase (PHGDH) Is Crucial for the Apoptotic Response Upon Serine Starvation,” The Journal of Biological Chemistry 290 (2015): 457–466.

[391] M. Doepner, I. Y. Lee, and T. W. Ridky, “Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine Synthesis,” The Journal of Investigative Dermatology 140 (2020): 2114–2116.

[392] J. W. Locasale, A. R. Grassian, T. Melman, et al., “Phosphoglycerate Dehydrogenase Diverts Glycolytic Flux and Contributes to Oncogenesis,” Nature Genetics 43 (2011): 869–874.

[393] M. Q. Nguyen, J. L. Teh, T. J. Purwin, et al., “Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition,” The Journal of Investigative Dermatology 140 (2020): 2242–2252.e2247.

[394] O. Hamid, C. Robert, A. Daud, et al., “Five-year Survival Outcomes for Patients With Advanced Melanoma Treated With pembrolizumab in KEYNOTE-001,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 30 (2019): 582–588.

[395] C. Robert, G. V. Long, B. Brady, et al., “Nivolumab in Previously Untreated Melanoma Without BRAF Mutation,” The New England Journal of Medicine 372 (2015): 320–330.

[396] A. Ribas, I. Puzanov, R. Dummer, et al., “Pembrolizumab versus Investigator-choice Chemotherapy for Ipilimumab-refractory Melanoma (KEYNOTE-002): A Randomised, Controlled, Phase 2 Trial,” The Lancet Oncology 16 (2015): 908–918.

[397] O. Hamid, I. Puzanov, R. Dummer, et al., “Final Analysis of a Randomised Trial Comparing pembrolizumab versus Investigator-choice Chemotherapy for ipilimumab-refractory Advanced Melanoma,” European Journal of Cancer (Oxford, England: 1990) 86 (2017): 37–45.

[398] S. L. Topalian, M. Sznol, D. F. McDermott, et al., “Survival, Durable Tumor Remission, and Long-term Safety in Patients With Advanced Melanoma Receiving nivolumab,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 32 (2014): 1020–1030.

[399] C. Robert, J. Schachter, G. V. Long, et al., “Pembrolizumab versus Ipilimumab in Advanced Melanoma,” The New England Journal of Medicine 372 (2015): 2521–2532.

[400] C. Robert, M. S. Carlino, C. McNeil, et al., “Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab versus Ipilimumab in Advanced Melanoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 3998–4003.

[401] C. Robert, A. Ribas, J. Schachter, et al., “Pembrolizumab versus ipilimumab in Advanced Melanoma (KEYNOTE-006): Post-hoc 5-year Results From an Open-label, Multicentre, Randomised, Controlled, Phase 3 Study,” The Lancet Oncology 20 (2019): 1239–1251.

[402] J. Larkin, V. Chiarion-Sileni, R. Gonzalez, et al., “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma,” The New England Journal of Medicine 373 (2015): 23–34.

[403] J. Larkin, V. Chiarion-Sileni, R. Gonzalez, et al., “Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma,” The New England Journal of Medicine 381 (2019): 1535–1546.

[404] F. S. Hodi, V. Chiarion-Sileni, R. Gonzalez, et al., “Nivolumab plus ipilimumab or nivolumab Alone versus ipilimumab Alone in Advanced Melanoma (CheckMate 067): 4-year Outcomes of a Multicentre, Randomised, Phase 3 Trial,” The Lancet Oncology 19 (2018): 1480–1492.

[405] M. Guida, N. Bartolomeo, P. Quaglino, et al., “No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study,” Cancers 13, no. 3 (2021): 475.

[406] M. C. Kirchberger, S. Ugurel, J. Mangana, et al., “MEK Inhibition May Increase Survival of NRAS-mutated Melanoma Patients Treated With Checkpoint Blockade: Results of a Retrospective Multicentre Analysis of 364 Patients,” European Journal of Cancer (Oxford, England: 1990) 98 (2018): 10–16.

[407] J. Mangana, P. F. Cheng, K. Schindler, et al., “Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated With Anti-CTLA-4 Antibodies: Association With Overall Survival?,” PLoS ONE 10 (2015): e0139438.

[408] A. Zaremba, P. Mohr, R. Gutzmer, et al., “Immune Checkpoint Inhibition in Patients With NRAS Mutated and NRAS Wild Type Melanoma: A Multicenter Dermatologic Cooperative Oncology Group Study on 637 Patients From the Prospective Skin Cancer Registry ADOREG,” European Journal of Cancer (Oxford, England: 1990) 188 (2023): 140–151.

[409] A. Panning, W. Samlowski, and G. Allred, “Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival After Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma,” Cancers 15, no. 13 (2023): 3527.

[410] D. B. Johnson, C. M. Lovly, M. Flavin, et al., “Impact of NRAS Mutations for Patients With Advanced Melanoma Treated With Immune Therapies,” Cancer Immunology Research 3 (2015): 288–295.

[411] A. A. N. Rose, S. M. Armstrong, D. Hogg, et al., “Biologic Subtypes of Melanoma Predict Survival Benefit of Combination Anti-PD1+Anti-CTLA4 Immune Checkpoint Inhibitors versus Anti-PD1 Monotherapy,” Journal for Immunotherapy of Cancer 9, no. 1 (2021): e001642.

[412] F. Dupuis, L. Lamant, E. Gerard, et al., “Clinical, Histological and Molecular Predictors of Metastatic Melanoma Responses to anti-PD-1 Immunotherapy,” British Journal of Cancer 119 (2018): 193–199.

[413] O. J. van Not, W. A. Blokx, A. J. van den Eertwegh, et al., “BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma,” JCO Precision Oncology 6 (2022): e2200018.

[414] W. Sun, Y. Xu, W. Yan, et al., “A Real-world Study of Adjuvant Anti-PD -1 Immunotherapy on Stage III Melanoma With BRAF, NRAS, and KIT Mutations,” Cancer Medicine 12 (2023): 15945–15954.

[415] Z. Mo, J. Liu, J. Zhang, Y. Deng, M. Xu, and Y. Jiang, “Association of NRAS Mutations and Tertiary Lymphoid Structure Formation With Clinical Outcomes of Adjuvant PD-1 Inhibitors for Acral Melanoma,” International Immunopharmacology 124 (2023): 110973.

[416] N. E. Thomas, S. N. Edmiston, A. Alexander, et al., “Association between NRAS and BRAF Mutational Status and Melanoma-Specific Survival among Patients with Higher-Risk Primary Melanoma,” JAMA Oncology 1 (2015): 359–368.

[417] A. N. Shoushtari, W. K. Chatila, A. Arora, et al., “Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27 (2021): 2226–2235.

[418] L. Zhou, X. Wang, Z. Chi, et al., “Association of NRAS Mutation with Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials,” Frontiers in Immunology 12 (2021): 691032.

[419] B. Tang, Z. Chi, Y. Chen, et al., “Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 26 (2020): 4250–4259.

[420] B. Tang, R. Duan, X. Zhang, et al., “Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients with Advanced Melanoma,” The Oncologist 29, no. 6 (2024): e822–e827.

[421] D. A. Erkes, W. Cai, I. M. Sanchez, et al., “Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis,” Cancer Discovery 10 (2020): 254–269.

[422] N. M. Durham, C. J. Nirschl, C. M. Jackson, et al., “Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to be Suppressed in Vivo,” PLoS ONE 9 (2014): e109080.

[423] C. J. Workman, L. S. Cauley, I. Kim, M. A. Blackman, D. L. Woodland, and D. A. A. Vignali, “Lymphocyte Activation Gene-3 (CD223) Regulates the Size of the Expanding T Cell Population Following Antigen Activation in Vivo,” Journal of Immunology (Baltimore, Md: 1950) 172 (2004): 5450–5455.

[424] S. J. Lee, S. J. Byeon, J. Lee, et al., “LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target,” Journal of Immunotherapy (Hagerstown, Md: 1997) 42, no. 8 (2019): 279–283.

[425] J. Su, Y. Fu, Z. Cui, et al., “Relatlimab: A Novel Drug Targeting Immune Checkpoint LAG-3 in Melanoma Therapy,” Frontiers in Pharmacology 14 (2023): 1349081.

[426] S. Woo, M. E. Turnis, M. V. Goldberg, et al., “Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape,” Cancer Research 72 (2012): 917–927.

[427] A. C. Anderson, N. Joller, and V. K. Kuchroo, “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors With Specialized Functions in Immune Regulation,” Immunity 44 (2016):989–1004.

[428] P. A. Ascierto, E. J. Lipson, R. Dummer, et al., “Nivolumab and Relatlimab in Patients with Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results from the Phase I/IIa RELATIVITY-020 Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 2724–2735.

[429] H. A. Tawbi, D. Schadendorf, E. J. Lipson, et al., “Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma,” The New England Journal of Medicine 386 (2022): 24–34.

[430] X. Chen, Y. Li, Y. Xie, et al., “Nivolumab and relatlimab for the Treatment of Melanoma,” Drugs of Today (Barcelona, Spain: 1998) 59 (2023): 91–104.

[431] C. L. Roland, K. D. Lynn, J. E. Toombs, S. P. Dineen, D. G. Udugamasooriya, and R. A. Brekken, “Cytokine Levels Correlate With Immune Cell Infiltration After Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer,” PLoS ONE 4 (2009): e7669.

[432] C. L. Roland, S. P. Dineen, K. D. Lynn, et al., “Inhibition of Vascular Endothelial Growth Factor Reduces Angiogenesis and Modulates Immune Cell Infiltration of Orthotopic Breast Cancer Xenografts,” Molecular Cancer Therapeutics 8 (2009): 1761–1771.

[433] S. Yasuda, M. Sho, I. Yamato, et al., “Simultaneous Blockade of Programmed Death 1 and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Induces Synergistic Anti-tumour Effect in Vivo,” Clinical and Experimental Immunology 172 (2013): 500–506.

[434] M. J. Jager, C. L. Shields, C. M. Cebulla, et al., “Uveal Melanoma,” Nature Reviews Disease Primers 6 (2020): 24.

[435] S. Popat, C. Grohé, J. Corral, et al., “Anti-angiogenic Agents in the Age of Resistance to Immune Checkpoint Inhibitors: Do They Have a Role in Non-oncogene-addicted Non-small Cell Lung Cancer?,” Lung Cancer (Amsterdam, Netherlands) 144 (2020): 76–84.

[436] B. I. Rini, E. R. Plimack, V. Stus, et al., “Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma,” The New England Journal of Medicine 380 (2019): 1116–1127.

[437] R. J. Motzer, K. Penkov, J. Haanen, et al., “Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma,” The New England Journal of Medicine 380 (2019): 1103–1115.

[438] Y. Tomita, R. Motzer, T. Choueiri, et al., “Efficacy and Safety of avelumab plus axitinib in Elderly Patients With Advanced Renal Cell Carcinoma: Extended Follow-up Results From JAVELIN Renal 101,” ESMO Open 7 (2022): 100450.

[439] R. S. Finn, M. Ikeda, A. X. Zhu, et al., “Phase Ib Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38 (2020): 2960–2970.

[440] V. Makker, N. Colombo, A. Casado Herráez, et al., “Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer,” The New England Journal of Medicine 386 (2022): 437–448.

[441] B. I. Rini, B. Escudier, P. Tomczak, et al., “Comparative Effectiveness of axitinib versus sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial,” Lancet (London, England) 378 (2011): 1931–1939.

[442] R. J. Motzer, B. Escudier, P. Tomczak, et al., “Axitinib versus sorafenib as Second-line Treatment for Advanced Renal Cell Carcinoma: Overall Survival Analysis and Updated Results From a Randomised Phase 3 Trial,” The Lancet Oncology 14 (2013): 552–562.

[443] X. Sheng, X. Yan, Z. Chi, et al., “Axitinib in Combination with Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody against Programmed Cell Death-1, in Patients with Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 37 (2019): 2987–2999.

[444] B. Tang, J. Mo, X. Yan, et al., “Real-world Efficacy and Safety of axitinib in Combination With Anti-programmed Cell Death-1 Antibody for Advanced Mucosal Melanoma,” European Journal of Cancer (Oxford, England: 1990) 156 (2021): 83–92.

[445] M. H. Taylor, C. Lee, V. Makker, et al., “Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 38 (2020): 1154–1163.

[446] A. Arance, L. de la Cruz-Merino, T. M. Petrella, et al., “Phase II LEAP-004 Study of Lenvatinib plus Pembrolizumab for Melanoma with Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 75–85.

[447] S. Tian, H. Quan, C. Xie, et al., “YN968D1 is a Novel and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase With Potent Activity in Vitro and in Vivo,” Cancer Science 102 (2011): 1374–1380.

[448] L. Mao, B. Lian, C. Li, et al., “Camrelizumab plus Apatinib and Temozolomide as First-Line Treatment in Patients with Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial,” JAMA Oncology 9 (2023): 1099–1107.

[449] L. Zitvogel and G. Kroemer, “Anticancer Immunochemotherapy Using Adjuvants With Direct Cytotoxic Effects,” The Journal of Clinical Investigation 119 (2009): 2127–2130.

[450] H. Inoue and K. Tani, “Multimodal Immunogenic Cancer Cell Death as a Consequence of Anticancer Cytotoxic Treatments,” Cell Death and Differentiation 21 (2014): 39–49.

[451] R. E. Merritt, A. Mahtabifard, R. E. Yamada, R. G. Crystal, and R. J. Korst, “Cisplatin Augments Cytotoxic T-lymphocyte-mediated Antitumor Immunity in Poorly Immunogenic Murine Lung Cancer,” The Journal of Thoracic and Cardiovascular Surgery 126 (2003): 1609–1617.

[452] P. Correale, M. T. Del Vecchio, M. La Placa, et al., “Chemotherapeutic Drugs May be Used to Enhance the Killing Efficacy of human Tumor Antigen Peptide-specific CTLs,” Journal of Immunotherapy (Hagerstown, Md: 1997) 31, no. 2 (2008): 132–147.

[453] J. W. Hodge, C. T. Garnett, B. Farsaci, et al., “Chemotherapy-induced Immunogenic Modulation of Tumor Cells Enhances Killing by Cytotoxic T Lymphocytes and Is Distinct From Immunogenic Cell Death,” International Journal of Cancer 133 (2013): 624–636.

[454] A. Sevko, T. Michels, M. Vrohlings, et al., “Antitumor Effect of paclitaxel Is Mediated by Inhibition of Myeloid-derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model,” Journal of Immunology (Baltimore, Md: 1950) 190 (2013): 2464–2471.

[455] R. Jamal, R. Lapointe, E. Cocolakis, et al., “Peripheral and Local Predictive Immune Signatures Identified in a Phase II Trial of ipilimumab With Carboplatin/Paclitaxel in Unresectable Stage III or Stage IV Melanoma,” Journal for Immunotherapy of Cancer 5 (2017): 83.

[456] N. Desai, V. Trieu, Z. Yao, et al., “Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-free, Albumin-bound paclitaxel, ABI-007, Compared With Cremophor-based paclitaxel,” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 12, no. 4 (2006): 1317–1324.

[457] H. Liu, M. Sun, Z. Liu, et al., “KRAS-enhanced Macropinocytosis and Reduced FcRn-mediated Recycling Sensitize Pancreatic Cancer to Albumin-conjugated Drugs,” Journal of Controlled Release: Official Journal of the Controlled Release Society 296 (2019): 40–53.

[458] J. Li, J. Wang, Y. Dingv, et al., “Efficacy and Safety of anti-PD-1 Inhibitor Combined With Nab-paclitaxel in Chinese Patients With Refractory Melanoma,” Journal of Cancer Research and Clinical Oncology 148 (2022): 1159–1169.

[459] C. Commisso, S. M. Davidson, R. G. Soydaner-Azeloglu, et al., “Macropinocytosis of Protein Is an Amino Acid Supply Route in Ras-transformed Cells,” Nature 497 (2013): 633–637.

[460] A. J. Christiansen, A. West, K. Banks, et al., “Eradication of Solid Tumors Using Histone Deacetylase Inhibitors Combined With Immune-stimulating Antibodies,” Proceedings of the National Academy of Sciences of the United States of America 108 (2011): 4141–4146.

[461] M. Zou, D. Jiang, T. Wu, et al., “Post-GWAS Functional Studies Reveal an RA-associated CD40-induced NF-kB Signal Transduction and Transcriptional Regulation Network Targeted by Class II HDAC Inhibitors,” Human Molecular Genetics 30 (2021): 823–835.

[462] M. Kroesen, P. R. Gielen, I. C. Brok, I. Armandari, P. M. Hoogerbrugge, and G. J. Adema, “HDAC Inhibitors and Immunotherapy; a Double Edged Sword?,” Oncotarget 5 (2014):6558–6572.

[463] D. Briere, N. Sudhakar, D. M. Woods, et al., “The Class I/IV HDAC Inhibitor Mocetinostat Increases Tumor Antigen Presentation, Decreases Immune Suppressive Cell Types and Augments Checkpoint Inhibitor Therapy,” Cancer Immunology, Immunotherapy: CII 67 (2018): 381–392.

[464] D. M. Woods, K. V. Woan, F. Cheng, et al., “T Cells Lacking HDAC11 Have Increased Effector Functions and Mediate Enhanced Alloreactivity in a Murine Model,” Blood 130 (2017): 146–155.

[465] J. S. Weber, B. A. Levinson, A. S. Laino, A. C. Pavlick, and D. M. Woods, “Clinical and Immune Correlate Results From a Phase 1b Study of the Histone Deacetylase Inhibitor Mocetinostat With ipilimumab and nivolumab in Unresectable Stage III/IV Melanoma,” Melanoma Research 32 (2022): 324–333.

[466] M. B. Atkins, M. T. Lotze, J. P. Dutcher, et al., “High-dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17 (1999): 2105–2116.

[467] R. W. Joseph, R. J. Sullivan, R. Harrell, et al., “Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma,” Journal of Immunotherapy (Hagerstown, Md: 1997) 35 (2012): 66–72.

[468] E. I. Buchbinder, J. P. Dutcher, G. A. Daniels, et al., “Therapy With High-dose Interleukin-2 (HD IL-2) in Metastatic Melanoma and Renal Cell Carcinoma Following PD1 or PDL1 Inhibition,” Journal for Immunotherapy of Cancer 7 (2019): 49.

[469] L. Bastholt, I. M. Svane, J. K. Bjerregaard, J. Herrstedt, A. Hróbjartsson, and H. Schmidt, “High-dose Interleukin-2 and Interferon as First-line Immunotherapy for Metastatic Melanoma: Long-term Follow-up in a Large Unselected Danish Patient Cohort,” European Journal of Cancer (Oxford, England: 1990) 115 (2019): 61–67.

[470] J. I. Clark, J. Singh, M. S. Ernstoff, et al., “A Multi-center Phase II Study of High Dose Interleukin-2 Sequenced With vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma,” Journal for Immunotherapy of Cancer 6 (2018): 76.

[471] M. J. Mooradian, A. Reuben, P. A. Prieto, et al., “A Phase II Study of Combined Therapy With a BRAF Inhibitor (vemurafenib) and Interleukin-2 (aldesleukin) in Patients With Metastatic Melanoma,” Oncoimmunology 7 (2018): e1423172.

[472] R. E. Hunger, C. U. Brand, M. Streit, et al., “Successful Induction of Immune Responses Against Mutant Ras in Melanoma Patients Using Intradermal Injection of Peptides and GM-CSF as Adjuvant,” Experimental Dermatology 10 (2001): 161–167.

[473] S. Kopetz, A. Grothey, R. Yaeger, et al., “Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer,” The New England Journal of Medicine 381 (2019): 1632–1643.

[474] J. Tabernero, A. Grothey, E. Van Cutsem, et al., “Encorafenib plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses From the BEACON Study,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39 (2021): 273–284.

[475] S. García-Roman, M. Garzón-Ibáñez, J. Bertrán-Alamillo, et al., “Vaccine Antibodies Against a Synthetic Epidermal Growth Factor Variant Enhance the Antitumor Effects of Inhibitors Targeting the MAPK/ERK and PI3K/Akt Pathways,” Translational Oncology 40 (2024): 101878.

[476] A. R. Aldous and J. Z. Dong, “Personalized Neoantigen Vaccines: A New Approach to Cancer Immunotherapy,” Bioorganic & Medicinal Chemistry 26 (2018): 2842–2849.

[477] C. Sun and S. Xu, “Advances in Personalized Neoantigen Vaccines for Cancer Immunotherapy,” Bioscience Trends 14 (2020): 349–353.

[478] S. K. Mørk, M. Kadivar, K. F. Bol, et al., “Personalized Therapy With Peptide-based Neoantigen Vaccine (EVX-01) Including a Novel Adjuvant, CAF®09b, in Patients With Metastatic Melanoma,” Oncoimmunology 11 (2022): 2023255.

[479] G. V. Long, P. F. Ferrucci, A. Khattak, et al., “KEYNOTE—D36: Personalized Immunotherapy With a Neoepitope Vaccine, EVX-01 and Pembrolizumab in Advanced Melanoma,” Future Oncology (London, England) 18 (2022): 3473–3480.

[480] Z. Wang and Y. J. Cao, “Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research,” Frontiers in Immunology 11 (2020): 176.

[481] J. S. Granhøj, A. Witness Præst Jensen, M. Presti, Ö. Met, I. M. Svane, and M. Donia, “Tumor-infiltrating Lymphocytes for Adoptive Cell Therapy: Recent Advances, Challenges, and Future Directions,” Expert Opinion on Biological Therapy 22, no. 5 (2022): 627–641.

[482] P. F. Robbins, M. El-Gamil, Y. F. Li, et al., “A Mutated Beta-catenin Gene Encodes a Melanoma-specific Antigen Recognized by Tumor Infiltrating Lymphocytes,” The Journal of Experimental Medicine 183 (1996): 1185–1192.

[483] M. E. Dudley, J. R. Wunderlich, P. F. Robbins, et al., “Cancer Regression and Autoimmunity in Patients After Clonal Repopulation With Antitumor Lymphocytes,” Science (New York, NY) 298 (2002): 850–854.

[484] S. Hu-Lieskovan, S. Mok, B. Homet Moreno, et al., “Improved Antitumor Activity of Immunotherapy With BRAF and MEK Inhibitors in BRAF(V600E) Melanoma,” Science Translational Medicine 7 (2015): 279ra241.

[485] A. A. Sarnaik, O. Hamid, N. I. Khushalani, et al., “Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39 (2021): 2656–2666.

[486] J. Chesney, K. D. Lewis, H. Kluger, et al., “Efficacy and Safety of lifileucel, a One-time Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy, in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapies: Pooled Analysis of Consecutive Cohorts of the C-144-01 Study,” Journal for Immunotherapy of Cancer 10, no. 12 (2022): e005755.

[487] A. R. Moore, S. C. Rosenberg, F. McCormick, and S. Malek, “RAS-targeted Therapies: Is the Undruggable Drugged?,” Nature Reviews Drug Discovery 19 (2020): 533–552.

[488] E. Tran, P. F. Robbins, Y. Lu, et al., “T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer,” The New England Journal of Medicine 375 (2016): 2255–2262.

[489] V. Verma, N. Jafarzadeh, S. Boi, et al., “MEK Inhibition Reprograms CD8(+) T Lymphocytes Into Memory Stem Cells With Potent Antitumor Effects,” Nature Immunology 22 (2021): 53–66.

[490] L. Dennison, A. A. Mohan, and M. Yarchoan, “Tumor and Systemic Immunomodulatory Effects of MEK Inhibition,” Current Oncology Reports 23 (2021): 23.

[491] N. Aguilera-Montilla, S. Chamorro, C. Nieto, et al., “Aryl Hydrocarbon Receptor Contributes to the MEK/ERK-dependent Maintenance of the Immature state of human Dendritic Cells,” Blood 121 (2013): e108–e117.

[492] H. Sumimoto, F. Imabayashi, T. Iwata, and Y. Kawakami, “The BRAF-MAPK Signaling Pathway Is Essential for Cancer-immune Evasion in human Melanoma Cells,” The Journal of Experimental Medicine 203 (2006): 1651–1656.

[493] M. Yarchoan, A. A. Mohan, L. Dennison, et al., “MEK Inhibition Suppresses B Regulatory Cells and Augments Anti-tumor Immunity,” PLoS ONE 14 (2019): e0224600.

[494] C. Song, M. Piva, L. Sun, et al., “Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations During MAPKi-Induced Melanoma Regression and Early Adaptation,” Cancer Discovery 7 (2017): 1248–1265.

[495] M. J. Allegrezza, M. R. Rutkowski, T. L. Stephen, et al., “IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors,” Cancer Research 76 (2016): 2561–2572.

[496] M. J. Allegrezza, M. R. Rutkowski, T. L. Stephen, et al., “Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis,” Cancer Research 76 (2016): 6253–6265.

[497] P. J. Ebert, J. Cheung, Y. Yang, et al., “MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination With PD-L1 Checkpoint Blockade,” Immunity 44 (2016): 609–621.

[498] A. Boni, A. P. Cogdill, P. Dang, et al., “Selective BRAFV600E Inhibition Enhances T-cell Recognition of Melanoma Without Affecting Lymphocyte Function,” Cancer Research 70 (2010): 5213–5219.

[499] L. J. Vella, A. Pasam, N. Dimopoulos, et al., “MEK Inhibition, Alone or in Combination With BRAF Inhibition, Affects Multiple Functions of Isolated Normal human Lymphocytes and Dendritic Cells,” Cancer Immunology Research 2 (2014): 351–360.

[500] W. Hugo, H. Shi, L. Sun, et al., “Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance,” Cell 162 (2015): 1271–1285.

[501] V. Paulitschke, O. Eichhoff, P. F. Cheng, M. P. Levesque, and C. Höller, “Proteomics Approaches to Understanding Mitogen-activated Protein Kinase Inhibitor Resistance in Melanoma,” Current Opinion in Oncology 28 (2016): 172–179.

[502] J. L. Orgaz, E. Crosas-Molist, A. Sadok, et al., “Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance,” Cancer Cell 37 (2020): 85–103.e109.

[503] L. Haas, A. Elewaut, C. L. Gerard, et al., “Acquired Resistance to Anti-MAPK Targeted Therapy Confers an Immune-evasive Tumor Microenvironment and Cross-resistance to Immunotherapy in Melanoma,” Nature Cancer 2 (2021): 693–708.

[504] C. Trojaniello, M. G. Vitale, and P. A. Ascierto, “Triplet Combination of BRAF, MEK and PD-1/PD-L1 Blockade in Melanoma: The More the Better?,” Current Opinion in Oncology 33 (2021): 133–138.

[505] M. S. Phadke, Z. Chen, J. Li, et al., “Targeted Therapy Given After Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models Through Sustained Antitumor Immunity,” Cancer Immunology Research 9 (2021): 554–567.

[506] P. A. Ascierto, M. Mandalà, P. F. Ferrucci, et al., “Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 212–221.

[507] M. B. Atkins, S. J. Lee, B. Chmielowski, et al., “Combination Dabrafenib and Trametinib versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 41 (2023): 186–197.

[508] A. Ribas, A. Algazi, P. A. Ascierto, et al., “PD-L1 Blockade in Combination With Inhibition of MAPK Oncogenic Signaling in Patients With Advanced Melanoma,” Nature Communications 11 (2020): 6262.

[509] R. J. Sullivan, O. Hamid, R. Gonzalez, et al., “Atezolizumab plus Cobimetinib and Vemurafenib in BRAF-mutated Melanoma Patients,” Nature Medicine 25 (2019): 929–935.

[510] A. Ribas, D. Lawrence, V. Atkinson, et al., “Combined BRAF and MEK Inhibition With PD-1 Blockade Immunotherapy in BRAF-mutant Melanoma,” Nature Medicine 25 (2019): 936–940.

[511] H. Gogas, B. Dréno, J. Larkin, et al., “Cobimetinib plus Atezolizumab in BRAF(V600) Wild-type Melanoma: Primary Results From the Randomized Phase III IMspire170 Study,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 32 (2021): 384–394.

[512] R. Dummer, G. V. Long, C. Robert, et al., “Randomized Phase III Trial Evaluating Spartalizumab plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 40 (2022): 1428–1438.

[513] P. F. Ferrucci, A. M. Di Giacomo, M. Del Vecchio, et al., “KEYNOTE-022 Part 3: A Randomized, Double-blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-mutant Melanoma,” Journal for Immunotherapy of Cancer 8, no. 2 (2020): e001806.

[514] A. Ribas, F. S. Hodi, M. Callahan, C. Konto, and J. Wolchok, “Hepatotoxicity With Combination of Vemurafenib and Ipilimumab,” The New England Journal of Medicine 368 (2013): 1365–1366.

[515] T. Gebregiworgis, J. Y. Chan, D. A. Kuntz, G. G. Privé, C. B. Marshall, and M. Ikura, “Crystal Structure of NRAS Q61K With a Ligand-induced Pocket near Switch II,” European Journal of Cell Biology 103 (2024): 151414.

[516] M. S. Carlino, J. Larkin, and G. V. Long, “Immune Checkpoint Inhibitors in Melanoma,” Lancet (London, England) 398 (2021): 1002–1014.

[517] U. Sahin, P. Oehm, E. Derhovanessian, et al., “An RNA Vaccine Drives Immunity in Checkpoint-inhibitor-treated Melanoma,” Nature 585 (2020): 107–112.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.